Bispecific GPC3xCD28 and GPC3xCD3 antibodies and combinations thereof for targeted killing of GPC3 positive malignant cells
Bispecific antibodies targeting GPC3xCD28 and GPC3xCD3 enhance T cell activation and tumoricidal activity, addressing the limitations of current cancer immunotherapies by synergistically killing GPC3-positive solid tumors.
Patent Information
- Application Number
- CN202380027590.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-07
- Filing Date
- 2023-03-14
- Publication Date
- 2024-12-06
AI Technical Summary
Current cancer immunotherapies, such as monoclonal antibodies and CAR T cells, have limited effectiveness in treating solid cancers, leaving many patients without effective treatment options, and the exploration of T cell activation through co-stimulatory signals is underdeveloped.
Development of bispecific antibodies targeting GPC3xCD28 and GPC3xCD3 to enhance T cell activation and tumoricidal activity by co-engaging GPC3 on tumor cells with CD28 on T cells, using specific antigen-binding domains with defined CDR sequences, and administering them in combination to activate the immune system.
The combination of GPC3xCD3 and GPC3xCD28 bispecific antibodies synergistically enhances tumor-specific T cell activation and killing of GPC3-positive malignant cells, providing a novel treatment option for solid tumors with improved efficacy over monotherapy.
Smart Images

Figure BDA0005042381510000201 
Figure BDA0005042381510000211 
Figure BDA0005042381510000221
Abstract
Description
[0001] Cross-reference to related applications
[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 319,709, filed on March 14, 2022, and U.S. Provisional Application No. 63 / 328,586, filed on April 7, 2022, the contents of each of which are incorporated herein by reference in their entirety.
[0003] Incorporation by Reference into the Sequence Listing
[0004] The contents of the electronic sequence listing (NOVI_725_001WO_SeqList_ST26.xml; size: 52,994 bytes; and creation date: March 13, 2023) are incorporated herein by reference in their entirety. Technical Field
[0005] The present invention relates to fully human bispecific antibodies (such as κλ bodies) targeting GPC3xCD28 (CD28 agonist) and bispecific antibodies targeting GPC3xCD3, and to the combination of GPC3xCD3 and GPC3xCD28 of the present invention. When GPC3 on tumor cells expressing GPC3 and CD28 on T cells are engaged, the combination therapy of the present invention can enhance T cell activation and tumoricidal activity compared to GPC3xCD3 monotherapy. The present invention further relates to methods of using such antibodies in the treatment of GPC3-positive malignancies. Background Art
[0006] Over the past few years, new approaches have been developed to stimulate the body's own immune cells to better attack and kill cancer cells. Examples of successful cancer immunotherapies are monoclonal antibodies that can block so-called immune checkpoints. Currently approved immune checkpoint inhibitors (ICIs) block CTLA-4 (e.g., Ipilimumab, sold under the brand name Yervoy), PD-1 (e.g., Pembrolizumab, sold under the brand name Keytruda and Cemiplimab, sold under the brand name Libtayo), and PD-L1 (e.g., Atezolizumab, sold under the brand name Tecentriq). ICIs can induce durable anti-tumor responses in several, but not all, cancer types, with responses limited to subsets of patients.
[0007] Other approved cancer immunotherapies include T cell bispecific antibodies, which bridge T cells to target cells expressing tumor-associated antigens (TAAs) via the CD3 receptor on T cells. A different strategy is the use of chimeric antigen receptor (CAR) T cells. Although very good anti-tumor responses have been observed when using T cell bispecific antibodies or CAR T cells to treat hematological malignancies, to date, these approaches have not had significant breakthroughs in the setting of solid cancers, leaving many cancer patients without treatment options.
[0008] "Thus, despite the success of these immunotherapies in some cancer types, a large proportion of cancer patients lack effective treatment options, highlighting the need for new treatments. The use of molecules capable of activating the immune system by targeting co-stimulatory signals on T cells has not been fully explored and could open the way to new treatment options for patients with solid cancers."
[0009] There is a need for compositions and methods for targeting T cell activation that can be used to treat solid cancers. Provided herein are methods and compositions that address this need. Summary of the invention
[0010] The present disclosure provides a bispecific antibody, comprising: a. a first antigen-binding domain, which binds to CD3; wherein the first antigen-binding domain comprises: i. a first heavy chain variable region, which comprises: a complementary determining region 1 (CDRH1) comprising an amino acid sequence of SEQ ID NO: 6; a complementary determining region 2 (CDRH2) comprising an amino acid sequence of SEQ ID NO: 7; and a complementary determining region 3 (CDRH3) comprising an amino acid sequence of SEQ ID NO: 8; and ii. a first light chain variable region, which comprises: a CDRL1 comprising an amino acid sequence of SEQ ID NO: 11; a CDRL2 comprising an amino acid sequence of SEQ ID NO: 12; and a CDRL3 comprising an amino acid sequence of SEQ ID NO: 13; and b. a second antigen-binding domain, which binds to GPC3, wherein the second antigen-binding domain comprises: i. a second heavy chain variable region, which comprises: a CDRH1 comprising an amino acid sequence of SEQ ID NO: 6; a CDRH2 comprising an amino acid sequence of SEQ ID NO: 7; and a CDRH3 comprising an amino acid sequence of SEQ ID NO: 8. NO:7; and CDRH3 comprising the amino acid sequence of SEQ ID NO:8; and ii. a second light chain variable region, the second light chain variable region having: 1. a CDRL1 comprising the amino acid sequence of SEQ ID NO:16; a CDRL2 comprising the amino acid sequence of SEQ ID NO:17; and CDRL3 comprising the amino acid sequence of SEQ ID NO:18; or 2. a CDRL1 comprising the amino acid sequence of SEQ ID NO:21; a CDRL2 comprising the amino acid sequence of SEQ ID NO:22; and CDRL3 comprising the amino acid sequence of SEQ ID NO:23.
[0011] In some embodiments, the first heavy chain variable region and the second heavy chain variable region comprise the amino acid sequence of SEQ ID NO: 9. In some embodiments, the first heavy chain and the second heavy chain comprise the amino acid sequence of SEQ ID NO: 10. In some embodiments, the first light chain variable region comprises the amino acid sequence of SEQ ID NO: 14. In some embodiments, the first light chain comprises the amino acid sequence of SEQ ID NO: 15.
[0012] In some embodiments, for the second light chain variable region, a. part b.ii.1. includes the amino acid sequence of SEQ ID NO:19; or b. part b.ii.2. includes the amino acid sequence of SEQ ID NO:24.
[0013] In some embodiments, for the second light chain, a. part b.ii.1. comprises the amino acid sequence of SEQ ID NO:20; or b. part b.ii.2. comprises the amino acid sequence of SEQ ID NO:25.
[0014] The present disclosure provides a bispecific antibody, comprising: a. a first antigen-binding domain, which binds to CD28; wherein the first antigen-binding domain comprises: i. a first heavy chain variable region, which comprises: CDRH1 comprising the amino acid sequence of SEQ ID NO: 1; CDRH2 comprising the amino acid sequence of SEQ ID NO: 2; and CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and ii. a first light chain variable region, which comprises: 1. CDRL1 comprising the amino acid sequence of SEQ ID NO: 41; CDRL2 comprising the amino acid sequence of SEQ ID NO: 42; and CDRL3 comprising the amino acid sequence of SEQ ID NO: 43; or 2. CDRL1 comprising the amino acid sequence of SEQ ID NO: 46; CDRL2 comprising the amino acid sequence of SEQ ID NO: 47; and CDRL3 comprising the amino acid sequence of SEQ ID NO: 48; or 3. CDRL1 comprising the amino acid sequence of SEQ ID NO: 51; CDRL2 comprising the amino acid sequence of SEQ ID NO: 52; and CDRL3 comprising the amino acid sequence of SEQ ID NO: NO:53; and b. a second antigen binding domain that binds to GPC3, wherein the second antigen binding domain comprises: i. a second heavy chain variable region, the second heavy chain variable region comprising: CDRH1 comprising the amino acid sequence of SEQ ID NO:1; CDRH2 comprising the amino acid sequence of SEQ ID NO:2; and CDRH3 comprising the amino acid sequence of SEQ ID NO:3; and ii. a second light chain variable region, the second light chain variable region comprising: 1. CDRL1 comprising the amino acid sequence of SEQ ID NO:26; CDRL2 comprising the amino acid sequence of SEQ ID NO:27; and CDRL3 comprising the amino acid sequence of SEQ ID NO:28; or 2. CDRL1 comprising the amino acid sequence of SEQ ID NO:31; CDRL2 comprising the amino acid sequence of SEQ ID NO:32; and CDRL3 comprising the amino acid sequence of SEQ ID NO:33; or 3. CDRL1 comprising the amino acid sequence of SEQ ID NO:36; CDRL2 comprising the amino acid sequence of SEQ ID NO:37; and CDRL3 comprising the amino acid sequence of SEQ ID NO:38. CDRL3 of the amino acid sequence of ID NO:38.
[0015] In some embodiments, the first heavy chain variable region and the second heavy chain variable region comprise the amino acid sequence of SEQ ID NO: 4. In some embodiments, the first heavy chain and the second heavy chain comprise the amino acid sequence of SEQ ID NO:5.
[0016] In some embodiments, for the first light chain variable region: a. part a.ii.1. includes the amino acid sequence of SEQ ID NO:44; b. part a.ii.2. includes the amino acid sequence of SEQ ID NO:49; or c. part a.ii.3. includes the amino acid sequence of SEQ ID NO:54.
[0017] In some embodiments, for the first light chain: a. part a.ii.1. includes the amino acid sequence of SEQ ID NO:45; b. part a.ii.2. includes the amino acid sequence of SEQ ID NO:50; or c. part a.ii.3. includes the amino acid sequence of SEQ ID NO:55.
[0018] In some embodiments, for the second light chain variable region: a. part b.ii.1. includes the amino acid sequence of SEQ ID NO:29; b. part b.ii.2. includes the amino acid sequence of SEQ ID NO:34; or c. part b.ii.3. includes the amino acid sequence of SEQ ID NO:39.
[0019] In some embodiments, for the second light chain: a. part b.ii.1. includes the amino acid sequence of SEQ ID NO:30; b. part b.ii.2. includes the amino acid sequence of SEQ ID NO:35; or c. part b.ii.3. includes the amino acid sequence of SEQ ID NO:40.
[0020] In some embodiments, the first light chain is κ and the second light chain is λ. In some embodiments, the first light chain is λ and the second light chain is κ.
[0021] In some embodiments, the bispecific antibody comprises an Fc domain comprising one or more amino acid substitutions that reduce binding to activated Fc receptors and / or reduce effector function. In some embodiments, the amino acid substitutions comprise L234A and L235A substitutions. In some embodiments, the amino acid substitutions comprise: i) L234A substitutions; ii) L235A substitutions; and iii) P329A, P329G, or P329R substitutions.
[0022] In some embodiments, the antibody has an IgG isotype. In some embodiments, the antibody is a human antibody.
[0023] The present disclosure provides a composition comprising any of the bispecific antibodies of the present disclosure.
[0024] The present disclosure provides a composition, comprising: a first bispecific antibody, the first bispecific antibody comprising: a. a first antigen-binding domain, the first antigen-binding domain binding to CD3; wherein the first antigen-binding domain comprises: i. a first heavy chain variable region, the first heavy chain variable region comprising: a complementarity determining region 1 (CDRH1) comprising an amino acid sequence of SEQ ID NO: 6; a complementarity determining region 2 (CDRH2) comprising an amino acid sequence of SEQ ID NO: 7; and a complementarity determining region 3 (CDRH3) comprising an amino acid sequence of SEQ ID NO: 8; and ii. a first light chain variable region, the first light chain variable region comprising: a CDRL1 comprising an amino acid sequence of SEQ ID NO: 11; a CDRL2 comprising an amino acid sequence of SEQ ID NO: 12; and a CDRL3 comprising an amino acid sequence of SEQ ID NO: 13; and b. a second antigen-binding domain, the second antigen-binding domain binding to GPC3, wherein the second antigen-binding domain comprises: i. a second heavy chain variable region, the second heavy chain variable region comprising: a CDRH1 comprising an amino acid sequence of SEQ ID NO: 6; a CDRH2 comprising an amino acid sequence of SEQ ID NO: 7; and a CDRH3 comprising an amino acid sequence of SEQ ID NO: 8. NO:7; and CDRH3 comprising the amino acid sequence of SEQ ID NO:8; and ii. a second light chain variable region, the second light chain variable region having: 1. a CDRL1 comprising the amino acid sequence of SEQ ID NO:16; a CDRL2 comprising the amino acid sequence of SEQ ID NO:17; and CDRL3 comprising the amino acid sequence of SEQ ID NO:18; or 2. a CDRL1 comprising the amino acid sequence of SEQ ID NO:21; a CDRL2 comprising the amino acid sequence of SEQ ID NO:22; and CDRL3 comprising the amino acid sequence of SEQ ID NO:23; and a second bispecific antibody, the second bispecific antibody comprising: a. a first antigen binding domain, the first antigen binding domain binds to CD28; wherein the first antigen binding domain comprises: i. a first heavy chain variable region, the first heavy chain variable region having: a CDRH1 comprising the amino acid sequence of SEQ ID NO:1; a CDRH2 comprising the amino acid sequence of SEQ ID NO:2; and a CDRL3 comprising the amino acid sequence of SEQ ID NO:24. NO:3; and ii. a first light chain variable region, the first light chain variable region comprising: 1. CDRL1 comprising the amino acid sequence of SEQ ID NO:41; CDRL2 comprising the amino acid sequence of SEQ ID NO:42; and CDRL3 comprising the amino acid sequence of SEQ ID NO:43; or 2.a second antigen binding domain that binds to GPC3, wherein the second antigen binding domain comprises: i. a second heavy chain variable region, the second heavy chain variable region comprising: CDRH1 comprising the amino acid sequence of SEQ ID NO: 1; CDRH2 comprising the amino acid sequence of SEQ ID NO: 2; and CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and ii. a second light chain variable region, the second light chain variable region comprising: 1. CDRL1 comprising the amino acid sequence of SEQ ID NO: 26; CDRL2 comprising the amino acid sequence of SEQ ID NO: 27; and CDRL3 comprising the amino acid sequence of SEQ ID NO: 3. NO:28; or 2. CDRL1 comprising the amino acid sequence of SEQ ID NO:31; CDRL2 comprising the amino acid sequence of SEQ ID NO:32; and CDRL3 comprising the amino acid sequence of SEQ ID NO:33; or 3. CDRL1 comprising the amino acid sequence of SEQ ID NO:36; CDRL2 comprising the amino acid sequence of SEQ ID NO:37; and CDRL3 comprising the amino acid sequence of SEQ ID NO:38.
[0025] In some embodiments, the composition enables tumor-specific T cell activation.
[0026] The present disclosure provides a method of reducing the proliferation of cancer cells and / or killing cancer cells, the method comprising contacting the cells with any one of the compositions of the present disclosure.
[0027] The present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject any one of the compositions of the present disclosure. In some embodiments, the cancer is GPC3 positive.
[0028] Unless otherwise defined, the meaning of all technical and scientific terms used herein is the same as that generally understood by those of ordinary skill in the art to which the present invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are expressly incorporated by reference as a whole. In the event of a conflict, this specification (including definitions) shall prevail. In addition, the materials, methods and examples described herein are illustrative only and are not intended to be limiting.
[0029] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims, and are encompassed therein. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figures 1A-1C Figure 2 shows the interaction between the GPC3xCD3 bispecific antibody (AD84L3-1 / N) of the present invention and Hep G2 cells expressing GPC3 ( Figure 1A ), Jurkat cells expressing CD3 ( Figure 1B ) and GPC3 and CD3 double negative SK-HEP-1 cells ( Figure 1C ) is a series of graphs showing concentration-dependent binding of . Figure 1A , 1B 1C and 1C show a comparison of binding between AD84L3-1 / N and ERY974, the latter used as a reference comparator. hIgG1 was used as an isotype control.
[0031] Figure 2A-2C Figure 2 shows the interaction between the GPC3xCD28 bispecific antibodies (AI3P44 / N and AI3P30 / N) of the present invention and FU97 cells expressing GPC3 ( Figure 2A ), Jurkat cells expressing CD28 ( Figure 2B ) and GPC3 and CD28 double negative TIB-153 cells ( Figure 2C ). The two GPC3xCD28 biAbs contain the same anti-CD28 AI3 arm paired with two GPC3 arms (P44 or P30), both of which bind to the distal portion of the GPC3 receptor. hIgG1 was used as an isotype control.
[0032] Figures 3A-3D Figure 2 shows the effect of one of the GPC3xCD28 bispecific antibodies of the present invention (AI3P44 / N) on GPC3-positive Hep G2 cells ( Figure 3A and Figure 3B ) and GPC3-negative SK-HEP-1 cells ( Figure 3C and 3D ) for T cell retargeted killing / lysis. Shown is the concentration (dose) dependent lysis of tumor cells by AD84L3-1 / N alone and in combination with different fixed concentrations (0.5; 0.1; 0.05 or 0.025 μg / mL) of AI3P44 / N. Effector cells were derived from two different healthy donors ( Figure 3A and 3C : Donor 1, and Figure 3B and 3D : PBMCs of donor 2). CD28 biAb synergizes with GPC3xCD3 to kill GPC3-positive Hep G2 cells. Killing is dose-dependent with the concentration of GPC3xCD28 biAb. Killing was not induced using the GPC3-negative SK-HEP-1 cell line. Y4L3-1 / N is a non-targeting CD3 monovalent antibody and was used as a negative control; hIgG1 was used as an isotype control. ERY974 monotherapy was used as a reference comparator.
[0033] Figures 4A-4C is a series of graphs showing T cell retargeted killing / lysis of the GPC3-positive Hep G2 cell line ( Figure 4A , 4B and 4C). When compared with a fixed dose (0.5; 0.1 or 0.05 μg / mL) of the GPC3xCD28 biAb of the present invention (AI3P44 / N( Figure 4A )、AI3P30 / N( Figure 4B ) or AI3P111( Figure 4C Dose response of the GPC3xCD3 bispecific antibody AD84L3-1 / N when combined with AI3xCD3 biAbs (Figure 2A). GPC3 arms P44 and P30 target membrane distal regions within GPC3 and therefore do not compete with the membrane proximal GPC3 arms of GPC3xCD3 biAbs (e.g., AD84). The P111 GPC3 arm binds proximal to the membrane, but again does not compete with the GPC3 arms of CD3 biAbs (e.g., AD84) for binding to GPC3. Synergy was observed for all combinations of GPC3xCD3 biAbs and GPC3xCD28 biAbs in killing GPC3-positive Hep G2 target cells. Killing was dose-dependent with the concentration of GPC3xCD28 biAb. TDCC comparison data showed that pairing the P111 arm with AI3 was less efficient in enhancing AD84L3-1 / N activity compared to the AI3P44 / N combination (1.5 and 2.5, respectively). Figure 4A and Figure 4C). Y4L3-1 / N is a monovalent antibody that targets only CD3, which does not bridge tumor cells and T cells, and is therefore used as a negative control; hIgG1 is used as an isotype control. ERY974, which is being tested in a clinical trial (Clin. Trials Gov. Reference NCT05022927), is included as a single-agent treatment and is used as a reference comparator for activity. Data are presented using a representative PBMC donor in each case. For more explanation, please see the text.
[0034] Figures 5A-5D is a series of graphs showing a comparison of two GPC3xCD28 biAbs generated using the same membrane distal GPC3 binding arm P44, which was paired with an anti-CD28 arm with different binding affinities to CD28, AI3 or AI10. The GPC3xCD28 biAbs of the invention (AI3P44 / N and AI10P44 / N) were cultured in the GPC3 expressing cell line HuH-7 ( Figure 5A ) and Jurkat cells expressing CD28 ( Figure 5B ). The GPC3 targeting arm showed similar binding signals to GPC3-positive cells for AI3P44 / N and AI10P44 / N ( Figure 5A In contrast, the CD28-binding portions of the two GPC3xCD28 biAbs showed superior binding signals to AI3 over AI10 on CD28-positive cells ( Figure 5B ). T cell retargeted killing / lysis of the GPC3-positive cell line HepG2 was observed ( Figure 5C and 5D ), and the GPC3xCD3 bispecific antibody AD84L3-1 / N in monotherapy and with a fixed dose (0.5; 0.1 or 0.05 μg / mL) of the GPC3xCD28 biAb of the present invention (i.e., AI3P44 / N ( Figure 5C ) and AI10P44 / N( Figure 5D)) dose response of the combination. Synergy between all combinations of GPC3xCD3 biAb and GPC3xCD28 biAb was observed in killing GPC3-positive Hep G2 target cells. Killing was dose-dependent with the concentration of GPC3xCD28 biAb. Based on the TDCC data, the affinity of the CD28 arm affects activity. At moderate concentrations of GPC3xCD28κλ bodies, lower TDCC activity was observed in combination with AI10P44 / N compared to AI3P44 / N. Y4L3-1 / N is a monovalent antibody that targets CD3 only, which does not bridge tumor cells and T cells and is therefore used as a negative control. ERY974, which is being tested in a clinical trial (Clin.Trials Gov. Reference NCT05022927), is included as a single-agent treatment and is used as a reference comparator for activity. As for the control, no killing was observed in the absence of GPC3xCD3biAb providing the GPC3 drive signal 1 ( Figure 5C and 5D ). Data are presented using a representative PBMC donor in each case.
[0035] Figures 6A-6E Figure 2 shows the GPC3xCD3 biAb (AD84L3-1 / N) and the GPC3xCD28 bispecific antibody of the present invention: AI3P30 / N (1 PBMC donor) ( Fig. 6A ), AI3P44 / N (three different PBMC donors) ( Figure 6B , 6C , 6D) and AI10P44 / N( Fig. 6E ) combinations on the GPC3-expressing cell line Hep 3B. In this cell line with lower GPC3 expression (i.e. Hep 3B, 60'000 GPC3 / cell), GPC3xCD3 (AD84L3-1 / N) alone has no or minimal killing effect. Strong synergistic killing effect of the combination of CD3 and CD28 biAbs in killing GPC3-positive target cells. Killing can be adjusted by varying the concentration of GPC3xCD28 biAbs. As negative controls, Y4L3-1 / N (monovalent antibody targeting CD3 only) was used alone and in combination with the GPC3xCD28 biAb of the invention; hIgG1 was used as an isotype control. ERY974, currently being tested in clinical trials (e.g. ClinicalTrials.gov identifier: NCT05022927), was included as a single-agent treatment and used as a reference comparator for activity.
[0036] Figures 7A-7Dis a series of graphs showing simultaneous measurement of T cell retargeted killing / lysis and pro-inflammatory cytokine secretion. T cell retargeted killing / lysis ( ( ) of the cell line Hep G2 expressing GPC3 (700'000 GPC3 / cell) by one of the GPC3xCD28 bispecific antibodies of the invention (AI3P44 / N) and GPC3xCD3 biAb (AD84L3-1 / N) Fig. 7A ). The secretion of IFN-γ, IL-6 and TNF-α is respectively Figure 7B , 7C and 7D. The combination of CD3 and CD28 biAbs resulted in a stronger induction of proinflammatory cytokine secretion compared to GPC3xCD3 monotherapy with AD84L3-1 / N. Cytokine levels depended on the concentration of CD28 biAb (AI3P44 / N). ERY974, used as a clinical comparator, showed a strong induction of cytokines, with levels mostly higher than those observed with the highest concentration of AD84L3-1 / N in combination with 0.05 or 0.1 μg / mL of AI3P44 / N. hIgG1 was used as an isotype control. ERY974 monotherapy was used as a clinical reference comparator.
[0037] Figures 8A-8D is a series of graphs showing T cell retargeted killing / lysis and pro-inflammatory cytokine secretion using AI3P30 / N instead of AI3P44 / N, the latter results are depicted in FIG7 . Simultaneous measurement of T cell retargeted killing / lysis and pro-inflammatory cytokine secretion. T cell retargeted killing / lysis (A13P30 / N) of the cell line Hep G2 expressing GPC3 by one of the GPC3xCD28 bispecific antibodies of the invention and GPC3xCD3biAb (AD84L3-1 / N) Fig. 8A ). The secretion of IFN-γ, IL-6 and TNF-α is respectively Figure 8B , 8C and 8D. The combination of CD3 and CD28 biAbs resulted in a stronger induction of proinflammatory cytokine secretion compared to GPC3xCD3 monotherapy with AD84L3-1 / N. Cytokine levels depended on the concentration of CD28 biAb (AI3P30 / N). ERY974, used as a clinical comparator, showed a strong induction of cytokines, with levels mostly higher than those observed with the highest concentrations of AD84L3-1 / N in combination with 0.05 or 0.1 μg / mL of AI3P30 / N. hIgG1 was used as an isotype control. ERY974 monotherapy was used as a clinical reference comparator.
[0038] Figures 9A-9H is shown to compare AI3P44 / N( Figures 9A-9D) and AI10P44 / N( Figures 9E-9H ) T cell retargeted killing / lysis and pro-inflammatory cytokine secretion. AI10 has lower binding affinity for CD28 than AI3. For comparability purposes, the same PBMC donor was used as the source of effector cells for each experiment. The cell line Hep G2 expressing GPC3 was used as the target. AI3P44 / N ( Fig.9A ) and AI10P44 / N( Fig.9E ) combined with T cell retargeting killing activity. IFN-γ( Fig. 9B and 9F ); IL-6( Fig. 9C and 9G ); TNF-α( Fig.9D and 9H ) secretion. Compared with 0.5 μg / mL of ERY974, higher killing rates were achieved, accompanied by similar or lower cytokine release. Cytokine release can be reduced, thereby reducing the concentration of GPC3xCD28, especially in the case of AI10P44 / N. At 0.1 μg / mL, AI3P44 / N killing was similar to ERY974 ( Fig.9A ), accompanied by lower cytokine release ( Figures 9B-9D AI10P44 / N also promoted killing at 0.1 μg / mL, but the overall level of killing was lower than that achieved by ERY974 ( Fig.9E ). Although a certain killing activity was maintained (E, when AI10P44 / N was added at 0.1 μg / mL, the maximum killing activity was at most 20%-25%), the cytokine release produced was low (FH, IFN-γ <5000 pg / mL, IL-6 <50 pg / mL, TNF-α <100 pg / mL). hIgG1 was used as an isotype control. ERY974 monotherapy was used as a reference comparator.
[0039] Figures 10A-10F is a series of graphs showing T cell retargeted killing / lysis using the CellTiter-Glo reader. As target cells, three GPC3 expressing cell lines were used, namely Hep G2 ( Figures 10A-10B , two PBMC donors are shown), Hep 3B ( Figures 10C-10D , two PBMC donors are shown) and HuH-7 ( Figures 10E-10F, two PBMC donors are shown), composed of GPC3xCD3biAb (AD84L3-1 / N) in combination with the GPC3xCD28 bispecific antibody of the invention (AI3P44 / N). In Hep 3B (60'000 GPC3 / cell) or HuH-7 (18'000 GPC3 / cell), GPC3xCD3 (AD84L3-1 / N) alone had no killing effect or only minimal killing effect. Synergistic killing effect of the combination of CD3 and CD28 biAb in killing all GPC3-positive target cells, regardless of their target expression level. As negative controls, Y4L3-1 / N (monovalent antibody targeting only CD3) was used alone and in combination with the GPC3xCD28 biAb of the invention; hIgG1 was used as an isotype control. ERY974 monotherapy was used as a reference comparator. DETAILED DESCRIPTION
[0040] The present invention includes GPC3xCD3 bispecific antibodies, GPC3xCD28 bispecific antibodies and compositions, the compositions including a combination of GPC3xCD3 bispecific antibodies and GPC3xCD28 bispecific antibodies, so as to induce T cell activation and killing of GPC3 (GPC3) positive tumor cells. Specifically, the present invention is based in part on a combination of two bispecific antibodies, one for co-engaging GPC3 expressed on the surface of target cells (e.g., tumor cells) to trigger CD3 positive T cell activation, and another bispecific antibody for co-engaging GPC3 (expressed on tumor cells) with CD28 (expressed on T cells). This results in clustering, and thus enhances tumor-specific T cell activation.
[0041] The present invention provides a fully human GPC3xCD3 bispecific antibody designed so that it can be administered in parallel with the GPC3xCD28 bispecific antibody of the present invention. Importantly, there is no binding competition with the target GPC3 between the GPC3xCD3 bispecific antibody and the GPC3xCD28 bispecific antibody. The present invention provides an agonist CD28 antigen binding molecule that enables T cells to co-engage with the GPC3 receptor on tumor cells. The present invention also provides a GPC3xCD3 bispecific antibody that mediates tumor-specific T cell activation (i.e., signal 1) and mediates increased tumor-specific T cell activation (signal 2) when administered in combination with the GPC3xCD28 bispecific antibody of the present invention. The GPC3xCD28 bispecific antibody of the present invention is the first GPC3xCD28 antibody described in the literature, which provides a new treatment option for patients with GPC3+ solid tumors. In addition, the combination of the GPC3xCD3 bispecific antibody of the present invention and the GPC3xCD28 bispecific antibody is a novel mechanism for activating the immune system by targeting co-stimulatory signals to T cells.
[0042] Glypican-3 (GPC3)
[0043] Glypican-3 (GPC3) is a heparan sulfate proteoglycan (HSPG). There are six glypican isoforms, GPC 1-6, which have a similar structure consisting of a 60-70 kDa protein attached to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, 14 conserved cysteine residues, and the last 50 residues at the carboxyl terminus modified by a heparan sulfate (HS) side chain. GPC3 is involved in cell growth, differentiation, and migration (Glypicans as Cancer Therapeutic Targets. Li N. et al. Trends Cancer. 2019 Nov 1; The Role of Glypicans in Cancer Progression and Therapy. Li N et al. J Histochem Cytochem. 2020 Dec;68(12):841-862). GPC3 is a highly tumor-specific antigen expressed during fetal development but is physiologically suppressed in adult tissues. Aberrant expression of GPC3 has been reported in hepatocellular carcinoma (HCC), lung squamous cell carcinoma (LSCC), testicular tumors, ovarian yolk sac tumors, melanoma, ovarian clear cell carcinoma, and other cancers (Glypican-3 induces mesenchymal to epithelial transition in human breast cancer cells. Fedra Castillo L. et al. Oncotarget. 2016 Sep 13;7(37):60133-60154; GPC-3 in hepatocellular carcinoma: current perspectives. Wu Y et al. J Hepatocell Carcinoma. 2016;3:63-67). GPC3 expression is associated with poor prognosis in HCC patients (Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: A meta-analysis. Li J. et al. World J Gastroenterol. 2014 May 28;20(20):6336-6344).Therefore, GPC3 is a biomarker and prognostic factor for HCC and an attractive immunotherapy target (Cancer immunotherapy-targeted glypican-3 or neoantigens. Shimizu Y. et al. Cancer Sci. 2018 Mar;109(3):531-541; Next-Generation Cancer Immunotherapy Targeting Glypican-3. Shimizu Y et al. Front Oncol. 2019;9:248).
[0044] CAR T cell therapy has shown clinical benefits in hematological malignancies, but has limited efficacy in solid tumors. Monoclonal antibodies targeting GPC3 have entered clinical testing, with Codrituzumab (GC33, RO5137382, ClinicalTrials.gov NCT04928677) as an example, where the response rate is low. Bispecific antibodies with potentially higher activity are exemplified by "ERY974", as described in WO2017 / 159287A1 (incorporated by reference as a whole), which include CDRs as shown in SEQ ID NOs: 42 to 45 of WO2017 / 159287A1 as CDRs.
[0045] ERY974 is a T-cell redirecting humanized IgG antibody with a common light chain that can bind to both GPC3 and CD3, thereby promoting cytotoxicity through the action of T-cell effectors. The GPC3 binder used in ERY974 is a humanized, affinity-matured, and stability-engineered version derived from the hGC33 antibody (An anti-glypican 3 / CD3 bispecific Tcell-redirecting antibody for treatment of solid tumors. Ishiguro T. et al., Sci Transl Med. 2017 Oct 4;9(410); Engineering abispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974. Shiraiwa et al., Methods, 2018). The CD3 binders used in ERY974 and rCE115 were derived from rat immunizations and humanized by a CDR grafting approach (Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3) / CD3 bispecific antibody, in patients with advanced solid tumors. Safran et al. Cancer Res (2021) 81(13_Suppl): CT111). The binding arm is specific for CD3ε. Lead antibodies against GPC3 and CD3ε were multidimensionally optimized to generate ERY974 using an hIgG4 backbone to reduce Fc effector function. ERY22 is a lead bispecific antibody composed of two H chains and two L chains. ERY22 was humanized and the common L chain was identified to generate humanized ERY with common L chain (hERY).hERY was further engineered to improve its binding affinity to the antigen as well as its physicochemical properties, such as enhanced stability, to generate ERY974 (Engineering bispecific antibodies with a common light chain: Identification and optimization of the anti-CD3ε and anti-GPC3 bispecific antibody ERY974. Shiraiwa et al., Methods, 2018).
[0046] ERY974 showed significant anti-tumor effects in preclinical tumor models that were unresponsive to treatment with immune checkpoint inhibitors such as PD-1 and CTLA-4 (An anti-glypican 3 / CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Ishiguro T. et al., Science Translational Medicine. 2017 Oct 04;9(410)). Further studies showed that ERY974 induced a high degree of inflammation in the tumor microenvironment, with toxicology studies in cynomolgus monkeys showing short-term elevated cytokine levels (An anti-glypican 3 / CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Ishiguro T. et al., Science Translational Medicine. 2017 Oct 04;9(410)). A significant improvement in antitumor activity in xenografts was achieved using a combination of ERY974 and chemotherapy (Anti-Glypican 3 / CD3 Bispecific T Cell Redirecting Antibodies for the Treatment of Solid Tumors. Ishiguro T. et al., Science Translational Medicine. 2017 Oct 04;9(410)). Early results from the first Phase I clinical trial of ERY974 (ClinicalTrials.gov NCT05022927) in solid tumors were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting (Results of a Phase 1 Dose Escalation Study of ERY974 Anti-Glypican 3 (GPC3) / CD3 Bispecific Antibody in Patients with Advanced Solid Tumors. Safran et al. Cancer Research (2021) 81(13_Suppl):CT111). To mitigate the toxicity of cytokine release syndrome (CRS), steroid prophylaxis and two-step in-patient escalation were implemented. 29 patients were enrolled at very low dose levels ranging from 0.003 μg / kg to 0.81 μg / kg. Dose-limiting toxicity of CRS (grade 2 and 3) was found at the 0.12 / 0.81 μg / kg dose regimen (Results of a Phase 1 Dose-Escalation Study of ERY974 Anti-GPC3 / CD3 Bispecific Antibody in Patients with Advanced Solid Tumors. Safran et al. Cancer Research (2021) 81(13_Suppl):CT111). Increased IL-6, TNF-a, and IL-8 were observed in patients, explaining the emergence of CRS. The tolerated dose of ERY974 is low. Clinical dosing may be complicated by a smaller therapeutic window and a lower probability of inducing a response, as determined preclinically with a steep dose-response curve.
[0047] Different GPC3xCD3 biAb formats are in preclinical development (A novel targeted GPC3 / CD3 bispecific antibody for the treatment hepatocellular carcinoma. Yu L. et al. Cancer Biol Ther. 2020;21(7):597-603; Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma. Yu L. et al., J Immunother. 2021 Apr 1;44(3):106-113; Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Effective in Inhibiting Tumor Growth in Mice. Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice). Chen X. et al. Mol Cancer Ther. 2022 Jan; 21(1): 149-158). One of them is the ScFv of anti-human CD3 antibody and the VH domain of anti-GPC3 antibody derived from monoclonal antibodies L2K and HN3, respectively. The ScFv fragment connected by a 15 amino acid long polyglycine / serine linker composed of (G4S)3 was fused to the Fc of IgG1 via the hinge region. Similarly, the C-terminus of the VH domain was fused to the Fc domain. P329G / L234A / L235A mutations (to inhibit Fc-mediated activity) and knob-hole mutations that produce problems were introduced into each Fc region. Preclinical data show in vitro and in vivo tumoricidal activity (Novel targeted GPC3 / CD3 bispecific antibodies for the treatment of hepatocellular carcinoma. Yu L. et al. Cancer Biol Ther. 2020; 21(7): 597-603). Highly engineered biAb formats should generate anti-drug antibodies (ADA) with a concomitant risk of exposure loss. No clinical trials have been reported so far.
[0048] CD28 is a key co-stimulatory receptor expressed at the surface of T cells. It belongs to a subfamily of co-stimulatory molecules, which are characterized by extracellular variable immunoglobulin-like domains, and also include CTLA-4, ICOS, PD-1 and BTLA. CD28 is expressed as a disulfide-bonded homodimer at the cell surface of T cells, and is present on approximately 80% of human CD4+T cells and 50% of CD8+T cells (Mir, MA (2015). Introduction to co-stimulation and co-stimulatory molecules (Introduction to Costimulation and Costimulatory Molecules). Developing co-stimulatory molecules for disease immunotherapy (Developing Costimulatory Molecules for Immunotherapy of Diseases), (Elsevier) Pages 1-43).
[0049] Despite the lack of intrinsic enzymatic activity, engagement of CD28 with its ligand results in specific phosphorylation and transcriptional signaling, which leads to metabolic changes and production of key cytokines, chemokines, and survival signals that are essential for long-term expansion and differentiation of T cells.
[0050] The main ligands of CD28 are CD80 (B7.1) and CD86 (B7.2), which are mainly expressed on the surface of professional antigen presenting cells (APCs). CD80 and CD86 differ in their expression patterns, multimeric states, and functions. Because CD28 and CTLA-4 are highly homologous, they compete for the same ligands. However, since CTLA-4 binds to these ligands with a higher affinity than CD28, CTLA-4 competes with CD28 for ligands and ultimately inhibits T cell responses.
[0051] Several anti-CD28 monoclonal antibodies have been developed. Some of these so-called superagonist (SA) antibodies were found to induce full activation of primary resting T cells even in the absence of TCR ligation (so-called "signal 1"). The first human study of one of these SA anti-CD28 antibodies, TGN1412, resulted in a severe inflammatory response, including a cytokine storm that was not anticipated in previous in vitro and in vivo studies, leading to chronic organ failure in all healthy volunteers who received TGN1412.
[0052] Targeted co-stimulation of CD28 using bispecific antibodies
[0053] To avoid safety issues associated with superagonist antibodies or systemic CD28 co-stimulation, tumor-targeted CD28 bispecific antibodies can be designed to limit co-stimulation of T cells near tumor cells. By pairing the agonist anti-CD28 arm with the anti-tumor associated antigen (TAA) arm, a molecule capable of bridging T cells with malignant cells expressing the selected TAA is generated. Because CD28 bispecific antibodies can only bind to CD28 monovalently, CD28 cannot accidentally cluster in the absence of TAA-positive target cells, thereby preventing systemic T cell activation. Even in the presence of TAA-positive cancer cells, which allow CD28 to cluster on the surface of T cells, the full cytotoxic potential of T cells can only be released in the presence of primary T cell stimulation through TCR. This is in contrast to the above-mentioned bivalent superagonist CD28 monoclonal antibody.
[0054] As mentioned above, the results of the first clinical trial using the T cell bispecific antibody TAAxCD3 in patients with advanced solid tumors were ineffective. Preclinical studies for the treatment of solid tumors have shown that the addition of costimulatory CD28 bispecific antibodies (providing additional T cell activation, i.e. ("signal 2")) enhances CD3 bispecific antibodies (which trigger T cell activation, i.e. ("signal 1")) (Skokos, D., Waite, JC, Haber, L., Crawford, A., Hermann, A., Ullman, E., Slim, R., Godin, S., Ajithdoss, D., Ye, X. et al. (2020). A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies). Science Translational Medicine 12, eaaw7888) or PD-(L)1 checkpoint inhibitors (Waite, JC, Wang, B., Haber, L., Hermann, A., Ullman, E., Ye, X., Dudgeon, D., Slim, R., Ajithdoss, DK, Godin, SJ et al. (2020). Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Science Translational Medicine 12, eaba2325). Examples of agonist TAAxCD28 bispecific antibodies are described in WO2019246514, WO2020198009, WO2020132066, WO2020132024, WO2020127618, WO2021259890, and WO2021155071, each of which is incorporated by reference in its entirety. Some corresponding molecules are currently being tested in clinical trials (ClinicalTrials.gov identifiers: NCT04590326, NCT03972657, NCT04626635). To date, such conditional CD28 costimulation for T cell activation has never been applied to GPC3-positive malignancies, and has never been combined with GPC3xCD3 bispecific antibodies to mediate cell-mediated tumoricidal activity and fine-tune related cytokine release.Pieris pharmaceuticals has developed another method for providing T cell activation signal 2 in the context of GPC3-positive malignancies, with the aim of inducing 4-1BB co-stimulatory effects in a tumor-localized manner. PRS-342 is an Anticalin-antibody bispecific fusion protein engineered for 4-1BB / GPC3 preclinical immuno-oncology, and the results have been published at AACR 2019 (Costimulatory T-cell engagement by PRS-342, a GPC3 / 4-1BB bispecific molecule, leads to activation of T-cells and tumor growth inhibition in a HCC humanized mouse model). Bossenmeier et al. Cancer Research (2019) 79 (13_ Supplement): 3268), showing that effective T cell activation is strictly dependent on the presence of GPC3-positive tumor cells. No clinical trials have been reported so far.
[0055] The present invention provides a new fully human GPC3xCD3 bispecific antibody designed to be administered in parallel with the GPC3xCD28 bispecific antibody also provided by the present invention. The GPC3xCD3 and GPC3xCD28 bispecific antibodies of the present invention have no cross-reactivity for GPC3 binding, i.e., they do not compete for binding to GPC3. The present invention provides agonist CD28 antigen binding molecules that enable co-engagement with GPC3 on tumor cells. The combination of these GPC3xCD28 and GPC3xCD3 bispecific antibodies mediates strong tumor-specific T cell activation.
[0056] The present invention describes novel GPC3xCD3 bispecific antibodies and novel GPC3xCD28 bispecific antibodies and combinations thereof. Comparative molecule "ERY974" has shown low dose CRS in the clinic, which in turn hinders potential therapeutic activity. Compared to ERY974, the GPC3xCD3 bispecific antibodies of the present invention can be administered at higher levels and have lower total levels of cytokine release, which is advantageous for therapeutic use. Specifically, the combination enables dosing regimens such as concurrent or sequential treatment, which may allow better control of dose-limiting CRS and concomitant increased activity. Typically, the strongest cytokine release is often seen at the first dose of TAAxCD3, and the release is much lower in subsequent doses. To avoid this problem, in the present invention, treatment with GPC3xCD3 at the beginning and subsequent treatment with a combination of GPC3xCD3 bispecific antibodies and GPC3xCD28 bispecific antibodies provides a method for alleviating cytokine release and achieving improved efficacy compared to GPC3xCD3 monotherapy. The activity of GPC3xCD28 in combination can be further fine-tuned using a panel of different molecules presented in the present invention, which is advantageous for therapeutic applications.
[0057] Exemplary GPC3xCD3 and GPC3xCD28 Bispecific Antibodies
[0058] The GPC3xCD3 bispecific antibody (further named "bispecific antibody GPC3xCD3" or "GPC3xCD3 bispecific antibody" or "GPC3xCD3 bispecific antibody") comprises a first portion that specifically binds to human GPC3 and a second binding portion that specifically binds to human CD3ε. For the GPC3xCD3 bispecific antibody, the letter number combination "AD84" or "AD95" represents the anti-GPC3 antibody arm of the bispecific antibody of the present invention, and "L3-1" (also referred to as "1A4") represents the anti-CD3 antibody arm.
[0059] The GPC3xCD28 bispecific antibody includes a first binding portion (i.e., antigen binding region) that specifically binds to human CD28 and a second binding portion (i.e., antigen binding region) that specifically binds to human GPC3 (a non-competitive binding domain compared to the GPC3xCD3 bispecific antibody). For the GPC3xCD28 bispecific antibody, "P44", "P30" and "P111" represent the anti-GPC3 antibody arm of the bispecific antibody of the present invention, and "AI3" or "AI10" represent the anti-CD28 antibody arm.
[0060] The structure of the κλ bispecific antibody (κλ body) of the present invention is almost indistinguishable from the structure of natural IgG. The present invention provides a combination of low immunogenicity and high efficacy. The GCP3xCD3 bispecific antibody comprises a common heavy chain, and in one embodiment, comprises a κ light chain in the GPC3 binding portion and a λ light chain in the CD3 binding portion. The GPC3xCD28 bispecific antibody comprises a different common heavy chain, and in one embodiment, comprises a κ light chain in the GPC3 binding portion and a λ light chain in the CD28 binding portion. The GPC3 binding arms of the GPC3xCD3 and GPC3xCD28 bispecific antibodies of the present invention target different domains within GPC3 to avoid binding competition on target cells.
[0061] The GPC3xCD3 and GPC3xCD28 bispecific antibodies of the present invention require an Fc portion with significantly reduced binding to FcγRs to avoid Fc-mediated effector functions or Fc receptor-mediated cross-linking of the bispecific antibodies.
[0062] In some embodiments, the heavy chain is a native heavy chain (i.e., does not contain any mutations ("wild type")). In some embodiments, the heavy chain comprises at least one mutation (i.e., has a "LALA" mutation or a "LALAPA" mutation). In some embodiments, the bispecific antibody comprises an amino acid substitution in each subunit of the Fc domain that reduces binding to an activated Fc receptor and / or reduces effector function, wherein the amino acid substitution is a substitution of L234A and L235A and / or P329, the substitution being selected from the group consisting of P329A, P329G and P329R (Kabat EU index numbering). In one embodiment, the bispecific antibody comprises an amino acid substitution L234A and L235A and P329A (Kabat EU index numbering) in each subunit of the Fc domain. L234A and L235A (LALA) indicate that the amino acid leucine at position 234 / 235 is replaced by alanine. P329A (PA) indicates that the amino acid proline at position 329 is replaced by alanine. " / N" in the bispecific antibody indicates that the Fc part carries the mutations L234A and L235A as well as P329A (LALAPA).
[0063] The bsAb of the present invention can be based on any different antibody formats previously described. Generally speaking, IgG-like formats are preferred because they provide advantageous properties such as long half-life and potential reduced immunogenicity, but any other molecular bispecific formats may also be used in the present invention. In certain embodiments, bispecific antibodies share a common heavy chain. The concept of obtaining bispecific antibodies using a common heavy chain has been previously described (exploiting light chains for the scalable generation and platform purification of native human bispecific IgG using light chains). Fischer N. et al. "Natural Communications (Nat Commun.)" February 12, 2015; 6: 6113; Optimizing assembly and production of native bispecific antibodies by codon de-optimization. Magistrelli G, Mabs. February / March 2017; 9 (2): 231-239). κλ bispecific antibodies are described, for example, in WO2014087248 (hereby incorporated by reference in its entirety).
[0064] Optionally, the bispecific antibody has different types of light chains. For example, one light chain is a kappa light chain and the other light chain is a lambda light chain (i.e., k1 antibody). Different light chains allow the bispecific to be easily purified using kappa and lambda selection resins.
[0065] In addition, the bispecific antibodies of the present invention can be prepared using the following techniques, including those disclosed in WO 2012 / 023053 filed on August 16, 2011, the contents of which are hereby incorporated by reference in their entirety. The method described in WO 2012 / 023053 generates bispecific antibodies that are structurally identical to human immunoglobulins. This type of molecule consists of two copies of a unique heavy chain polypeptide, a first light chain variable region fused to a constant kappa domain, and a second light chain variable region fused to a constant lambda domain. Each binding site exhibits a different antigenic specificity, to which both the heavy chain and the light chain contribute. The light chain variable region can be of the lambda or kappa family and is preferably fused to the lambda and kappa constant domains, respectively. This is preferred to avoid the generation of non-natural polypeptide connections.
[0066] However, the bispecific antibodies of the present invention can also be obtained by fusing a κ light chain variable domain to a constant λ domain to obtain a first specificity and fusing a λ light chain variable domain to a constant κ domain to obtain a second specificity. The bispecific antibodies described in WO2012 / 023053 are referred to as IgGκλ antibodies or "κλ bodies", which are a new fully human bispecific IgG format. This κλ body format allows affinity purification of bispecific antibodies that are indistinguishable from standard IgG molecules with properties that are indistinguishable from standard monoclonal antibodies, and is therefore advantageous compared to previous formats.
[0067] In addition to the above methods, the bispecific antibodies of the present invention can also be generated in vitro in a cell-free environment by introducing asymmetric mutations in the CH3 regions of two monospecific homodimeric antibodies and forming bispecific heterodimeric antibodies from two parental monospecific homodimeric antibodies under reducing conditions to allow disulfide bond isomerization according to the method described in the following document: International Patent Publication No. WO2011 / 131746. In the method, the first monospecific bivalent antibody and the second monospecific bivalent antibody are engineered to have certain substitutions at the CH3 domain that promote heterodimer stability; the antibodies are incubated together under reducing conditions sufficient to allow disulfide bond isomerization of cysteine in the hinge region; thereby generating a bispecific antibody by Fab arm exchange.
[0068] The antibodies of the present invention have two or more antigen binding domains and are bispecific. The bispecific antibodies of the present invention include antibodies having a full-length antibody structure or a partial-length antibody structure (such as Fab).
[0069] As used herein, "full-length antibody" refers to an antibody having two full-length antibody heavy chains and two full-length antibody light chains. A full-length antibody heavy chain (HC) is composed of the well-known heavy chain variable and constant domains VH, CH1, CH2, and CH3. A full-length antibody light chain (LC) is composed of the well-known light chain variable and constant domains VL and CL. A full-length antibody may lack a C-terminal lysine (K) in one or both heavy chains.
[0070] The term "Fab-arm" or "half molecule" refers to one heavy chain-light chain pair that specifically binds to an antigen.
[0071] The full-length bispecific antibodies of the present invention can be generated, for example, as follows: using Fab arm exchange (or half-molecule exchange) between two monospecific bivalent antibodies, by introducing substitutions at the heavy chain CH3 interface in each half molecule to promote the formation of heterodimers of two antibody half molecules with different specificities in a cell-free environment in vitro or using co-expression. The Fab arm exchange reaction is the result of a disulfide bond isomerization reaction and CH3 domain dissociation-association. The heavy chain disulfide bonds in the hinge region of the parent monospecific antibody are reduced. The resulting free cysteine of one of the parent monospecific antibodies forms an inter-heavy chain disulfide bond with a cysteine residue of a second parent monospecific antibody molecule, while the CH3 domain of the parent antibody is released and re-formed by dissociation-association. The CH3 domain of the Fab arm can be engineered to promote heterodimerization rather than homodimerization. The resulting product is a bispecific antibody with two Fab arms or half molecules, each of which binds to a different epitope.
[0072] As used herein, "homodimerization" refers to the interaction of two heavy chains having the same CH3 amino acid sequence. As used herein, "homodimer" refers to an antibody having two heavy chains having the same CH3 amino acid sequence.
[0073] As used herein, "heterodimerization" refers to the interaction of two heavy chains with different CH3 amino acid sequences. As used herein, "heterodimer" refers to an antibody with two heavy chains with different CH3 amino acid sequences.
[0074] A "knob-in-hole" strategy (see, e.g., PCT International Publication No. WO 2006 / 028936) can be used to generate full-length bispecific antibodies. In brief, selected amino acids that form the interface of the CH3 domains in human IgG can be mutated at positions that affect the interaction of the CH3 domains to promote heterodimer formation. Amino acids with small side chains (holes) are introduced into the heavy chain of an antibody that specifically binds a first antigen, and amino acids with large side chains (knobs) are introduced into the heavy chain of an antibody that specifically binds a second antigen. After co-expression of the two antibodies, heterodimers are formed due to the preferential interaction of the heavy chain with the "hole" with the heavy chain with the "knob". Exemplary CH3 substitution pairs that form a knob and hole are (expressed as modified position in the first CH3 domain of the first heavy chain / modified position in the second CH3 domain of the second heavy chain): T366Y / F405A, T366W / F405W, F405W / Y407A, T394W / Y407T, T394S / Y407A, T366W / T394S, F405W / T394S, and T366W / T366S_L368A_Y407V.
[0075] Other strategies may be used, such as using electrostatic interactions to promote heavy chain heterodimerization by replacing positively charged residues at one CH3 surface and negatively charged residues at a second CH3 surface, as described in U.S. Patent Publication No. US2010 / 0015133; U.S. Patent Publication No. US2009 / 0182127; U.S. Patent Publication No. US2010 / 028637 or U.S. Patent Publication No. US2011 / 0123532. In other strategies, heterodimerization can be promoted by the following substitutions (represented as modified position in the first CH3 domain of the first heavy chain / modified position in the second CH3 domain of the second heavy chain): L351Y_F405A_Y407V / T394W, T366I_K392M_T394W / F405A_Y407V, T366L_K392M_T394W / F405A_Y407V, L351Y_Y407V / T394W. 7A / T366A_K409F, L351Y_Y407A / T366V_K409F, Y407A / T366A_K409F or T350V_L351Y_F405A_Y407V / T350V_T366L_K392L_T394W, as described in the following documents: U.S. Patent Publication No. US2012 / 0149876 or U.S. Patent Publication No. US2013 / 0195849.
[0076] Exemplary CD28, CEA and MSLN antibodies that can be used to engineer bispecific molecules include antibodies disclosed herein. Exemplary anti-GPC3 antibodies from which the GPC3 antigen binding region can be derived include "AD843" or "AD95" antibodies. Exemplary anti-GPC3 antibodies from which the GPC3 antigen binding region can be derived include "P44", "P30" or "P111" antibodies. Exemplary anti-CD28 antibodies from which the CD28 antigen binding region can be derived include "AI3", "AI10" or "AI13" antibodies. Exemplary anti-CD3 antibodies from which the CD3 antigen binding region can be derived include "L3-1" (also known as "1A4") antibodies. Table 1 shows the amino acid sequences of regions of antibodies of the present disclosure.
[0077] Table 1. Exemplary amino acid sequences of the present disclosure
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084] Tables 2 and 3 show exemplary bispecific antibodies of the present disclosure. The nomenclature for each antibody is shown, and the individual first light chain, second light chain, and heavy chain regions of the κλ body of the present disclosure are described.
[0085] Table 2: Exemplary GPC3xCD3 bispecific antibodies of the present disclosure
[0086]
[0087] Table 3: Exemplary GPC3×CD28 bispecific antibodies of the present disclosure
[0088]
[0089]
[0090] In some embodiments, the AD84L3-1 / N bispecific antibody has: a first heavy chain comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO:6, a CDRH2 comprising the amino acid sequence of SEQ ID NO:7, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:8; a first light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO:11, a CDRL2 comprising the amino acid sequence of SEQ ID NO:12, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:13; and a second heavy chain comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO:6, a CDRH2 comprising the amino acid sequence of SEQ ID NO:7, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:8; and a second light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO:16, a CDRL2 comprising the amino acid sequence of SEQ ID NO:17, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:18.
[0091] In some embodiments, the AD84L3-1 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:14, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:19.
[0092] In some embodiments, the AD84L3-1 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO: 10, a first light chain comprising the amino acid sequence of SEQ ID NO: 15, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 10, and a second light chain comprising the amino acid sequence of SEQ ID NO: 20.
[0093] In some embodiments, the AD95L3-1 / N bispecific antibody has: a first heavy chain comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO:6, a CDRH2 comprising the amino acid sequence of SEQ ID NO:7, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:8; a first light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO:11, a CDRL2 comprising the amino acid sequence of SEQ ID NO:12, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:13; and a second heavy chain comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO:6, a CDRH2 comprising the amino acid sequence of SEQ ID NO:7, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:8; and a second light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO:21, a CDRL2 comprising the amino acid sequence of SEQ ID NO:22, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:23.
[0094] In some embodiments, the AD95L3-1 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:14, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:24.
[0095] In some embodiments, the AD95L3-1 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:10, a first light chain comprising the amino acid sequence of SEQ ID NO:15, a second heavy chain comprising the amino acid sequence of SEQ ID NO:10, and a second light chain comprising the amino acid sequence of SEQ ID NO:25.
[0096] In some embodiments, the AI10P44 / N bispecific antibody has: a first heavy chain, comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 46, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 47, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 48; and a second heavy chain, comprising: the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 26, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 28.
[0097] In some embodiments, the AI10P44 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:49, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:29.
[0098] In some embodiments, the AI10P44 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:50, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:30.
[0099] In some embodiments, the AI10P30 / N bispecific antibody has: a first heavy chain, comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 46, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 47, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 48; and a second heavy chain, comprising: the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 31, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 32, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 33.
[0100] In some embodiments, the AI10P30 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:49, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:34.
[0101] In some embodiments, the AI10P30 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:50, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:35.
[0102] In some embodiments, the AI10P111 / N bispecific antibody has: a first heavy chain, comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 46, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 47, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 48; and a second heavy chain, comprising: the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 36, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 37, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 38.
[0103] In some embodiments, the AI10P111 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:49, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:39.
[0104] In some embodiments, the AI10P111 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:50, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:40.
[0105] In some embodiments, the AI3P44 / N bispecific antibody has: a first heavy chain, comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 41, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 42, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 43; and a second heavy chain, comprising: an amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 26, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 28.
[0106] In some embodiments, the AI3P44 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:44, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:29.
[0107] In some embodiments, the AI3P44 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:45, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:30.
[0108] In some embodiments, the AI3P30 / N bispecific antibody has: a first heavy chain, comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 41, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 42, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 43; and a second heavy chain, comprising: an amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 31, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 32, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 33.
[0109] In some embodiments, the AI3P30 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:44, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:34.
[0110] In some embodiments, the AI3P30 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:45, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:35.
[0111] In some embodiments, the AI3P111 / N bispecific antibody comprises: a first heavy chain comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 41, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 42, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 43; and a second heavy chain comprising: an amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 36, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 37, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 38.
[0112] In some embodiments, the AI3P111 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:44, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:39.
[0113] In some embodiments, the AI3P111 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:45, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:40.
[0114] In some embodiments, the AI13P44 / N bispecific antibody has: a first heavy chain, comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 51, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 52, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 53; and a second heavy chain, comprising: the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 26, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 28.
[0115] In some embodiments, the AI13P44 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:54, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:29.
[0116] In some embodiments, the AI13P44 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:55, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:30.
[0117] In some embodiments, the AI13P30 / N bispecific antibody has: a first heavy chain, comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 51, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 52, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 53; and a second heavy chain, comprising: an amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain, comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 31, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 32, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 33.
[0118] In some embodiments, the AI13P30 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:54, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:34.
[0119] In some embodiments, the AI13P30 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:55, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:35.
[0120] In some embodiments, the AI13P111 / N bispecific antibody comprises: a first heavy chain comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; a first light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 51, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 52, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 53; and a second heavy chain comprising: the amino acid sequence of SEQ ID NO: 1, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and a second light chain comprising: a CDRL1 comprising the amino acid sequence of SEQ ID NO: 36, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 37, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 38.
[0121] In some embodiments, the AI13P111 / N bispecific antibody has: a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, a first light chain variable region comprising the amino acid sequence of SEQ ID NO:54, a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, and a second light chain variable region comprising the amino acid sequence of SEQ ID NO:39.
[0122] In some embodiments, the AI13P111 / N bispecific antibody has: a first heavy chain comprising the amino acid sequence of SEQ ID NO:5, a first light chain comprising the amino acid sequence of SEQ ID NO:55, a second heavy chain comprising the amino acid sequence of SEQ ID NO:5, and a second light chain comprising the amino acid sequence of SEQ ID NO:40.
[0123] The present disclosure provides a composition comprising a first bispecific antibody of the present disclosure (GPC3×CD3) and a second bispecific antibody of the present disclosure (GPC3×CD28).
[0124] Table 4: Exemplary compositions
[0125]
[0126] In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI10P44 / N. In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI10P30 / N. In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI10P111 / N. In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI3P44 / N. In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI3P30 / N. In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI3P111 / N. In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI13P44 / N. In some embodiments, the composition comprises a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI13P30 / N. In some embodiments, the composition includes a first bispecific antibody AD84L3-1 / N and a second bispecific antibody AI13P111 / N.
[0127] In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI10P44 / N. In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI10P30 / N. In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI10P111 / N. In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI3P44 / N. In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI3P30 / N. In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI3P111 / N. In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI13P44 / N. In some embodiments, the composition comprises a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI13P30 / N. In some embodiments, the composition includes a first bispecific antibody AD95L3-1 / N and a second bispecific antibody AI13P111 / N.
[0128] How to use
[0129] The therapeutic formulations of the invention comprising the bispecific antibodies of the invention are used to treat cancer or alleviate symptoms associated with cancer, such as, by way of non-limiting example, hepatocellular carcinoma HCC and other cancers expressing GPC3. The invention also provides methods for treating cancer or alleviating symptoms associated with cancer. The treatment regimen is performed by identifying a subject (e.g., a human patient having cancer (or at risk of having cancer)) using standard methods.
[0130] The effectiveness of the treatment is determined in conjunction with any known method for diagnosing or treating the particular immune-related disorder. Alleviation of one or more symptoms of the immune-related disorder indicates that the antibody confers a clinical benefit.
[0131] Pharmaceutical composition
[0132] The antibodies of the present invention (also referred to herein as "active compounds") and their derivatives, fragments, analogs and homologues can be incorporated into pharmaceutical compositions suitable for administration. Such compositions generally comprise an antibody and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delay agents compatible with drug administration, etc. Suitable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, which is a standard reference text in the field and is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution and 5% human serum albumin. Liposomes and non-aqueous vehicles such as non-volatile oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active compound, their use in the composition is covered. Supplementary active compounds may also be incorporated into the composition.
[0133] The pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous applications may include the following components: a sterile diluent, such as water for injection, saline solution, non-volatile oil, polyethylene glycol, glycerol, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates, or phosphates; and agents for adjusting tension, such as sodium chloride or dextrose. pH can be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be packaged in ampoules, disposable syringes, or multidose vials made of glass or plastic.
[0134] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF Corporation, Percival, NJ) TM (BASF, Parsippany, NJ)) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that there is easy injection. It must be stable under manufacturing and storage conditions, and must prevent the contamination of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of a dispersion, and by using a surfactant. The prevention of microbial action can be achieved by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents in the composition, such as sugars, polyols (such as mannitol, sorbitol), sodium chloride. The absorption of the injectable composition can be extended by including an agent such as aluminum monostearate and gelatin that delays absorption in the composition.
[0135] Sterile injectable solutions can be prepared by incorporating the active compound in the desired amount in an appropriate solvent together with one or a combination of ingredients listed above, followed by filtration sterilization if necessary. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other desired ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation methods are vacuum drying and freeze drying, which produce a powder of the active ingredient plus any other desired ingredients from its previously sterile filtered solution.
[0136] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.
[0137] Systemic administration can also be carried out by transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are well known in the art, and for example, for transmucosal administration, comprise detergents, bile salts and fusidic acid derivatives. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gel or cream as well known in the art.
[0138] The compounds may also be prepared in the form of suppositories (eg, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
[0139] In one embodiment, the active compound is prepared with a carrier (such as a controlled release formulation, which includes an implant and a microencapsulated delivery system) that protects the compound from rapid elimination from the body. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. The method for preparing such preparations will be apparent to those skilled in the art. The material can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (comprising liposomes targeted to infected cells with monoclonal antibodies against antiviral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0140] It is particularly advantageous to formulate the composition in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as unitary dosages for subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the present invention are dictated by and directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved, as well as the limitations inherent in the art of compounding such active compounds for individual treatment.
[0141] The pharmaceutical compositions can be included in a container, pack or dispenser or other article together with instructions for administration.
[0142] definition
[0143] As used herein, including the appended claims, singular forms such as "a," "an," and "the" include their plural referents unless the context clearly dictates otherwise.
[0144] "Affinity" refers to the sum strength of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity of 1:1 interactions between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X to its partner Y can generally be represented by a dissociation constant (K.sub.D). Affinity can be measured by common methods known in the art, including KinExA and Biacore and Octet.
[0145] As used herein, the term "antibody" includes, but is not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies), fully human antibodies, and chimeric antibodies.
[0146] As used herein, unless otherwise indicated, "antigen-binding fragment" refers to an antigen-binding fragment of an antibody, i.e., an antibody fragment that retains the ability to bind to an antigen bound by a full-length antibody, such as a fragment that retains one or more CDR regions. Examples of antibody-binding fragments include, but are not limited to, Fab, Fab', F(ab').sub.2, Fv fragments, and individual antibody heavy or light chains, and individual heavy or light chain variable regions.
[0147] "Fab fragment" consists of a light chain and the CH1 and variable region of a heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. "Fab fragment" can be the product of papain cleavage of an antibody.
[0148] The "Fc" region contains two heavy chain fragments, which include the CH2 domain and CH3 domain of the antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domain.
[0149] A "Fab' fragment" contains one light chain and a portion or fragment of one heavy chain, which portion or fragment contains the VH domain and the CH1 domain and the region between the CH1 and CH2 domains, so that an interchain disulfide bond can be formed between the two heavy chains of the two Fab' fragments to form a F(ab').sub.2 molecule.
[0150] A "F(ab')2 fragment" contains two light chains and two heavy chains comprising a portion of the constant region between the CH1 and CH2 domains, such that an interchain disulfide bond is formed between the two heavy chains. The F(ab').sub.2 fragment is thus composed of two Fab' fragments held together by a disulfide bond between the two heavy chains. A "F(ab')2 fragment" can be the product of pepsin cleavage of an antibody. An "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant region.
[0151] "Isolated antibody" refers to a purified state and in such context means that the molecule is substantially free of other biomolecules such as nucleic acids, proteins, lipids, carbohydrates, or other materials such as cellular debris and growth medium. Generally, the term "isolated" is not intended to refer to the complete absence of such materials or to the absence of water, buffers, or salts unless they are present in amounts that substantially interfere with experimental or therapeutic uses of the binding compounds as described herein.
[0152] As used herein, the term "monoclonal antibody" refers to a substantially homogeneous antibody population, that is, except for the possible naturally occurring mutations that may be present in trace amounts, the antibody molecules constituting the population are identical in amino acid sequence. On the contrary, conventional (polyclonal) antibody preparations are generally included in a variety of different antibodies with different amino acid sequences in their variable domains, and these antibodies are generally specific to different epitopes. The modifier "monoclonal" indicates that the characteristic of the antibody is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibody to be produced by any specific method. For example, the monoclonal antibody to be used according to the present invention can be prepared by the hybridization method first described by the following document: Kohler et al. (1975) "Nature (Nature)" 256:495, or can be prepared by a recombinant DNA method (see, for example, U.S. Patent No. 4,816,567). "Monoclonal antibodies" can also be isolated from phage antibody libraries using the techniques described in the following literature: for example, Clackson et al. (1991) Nature 352: 624-628 and Marks et al. (1991) J. Mol. Biol. 222: 581-597. See also Presta (2005) J. Allergy Clin. Immunol. 116: 731.
[0153] The term "fully human antibody" refers to an antibody that contains only human immunoglobulin protein sequences. If produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell, a fully human antibody may contain mouse carbohydrate chains. Similarly, a "mouse antibody" refers to an antibody that contains only mouse immunoglobulin sequences. Alternatively, a fully human antibody may contain rat carbohydrate chains if produced in a rat, in a rat cell, or in a hybridoma derived from a rat cell. Similarly, a "rat antibody" refers to an antibody that contains only rat immunoglobulin sequences.
[0154] In general, the basic "antibody" structural unit comprises a tetramer. In a monospecific antibody, each tetramer comprises two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain comprises a "variable region" or "variable domain" of about 100 to 110 or more amino acids that are primarily responsible for antigen recognition. The carboxyl-terminal portion of the heavy chain may define a constant region that is primarily responsible for effector function.
[0155] Usually, human constant light chains are divided into kappa light chains and lambda light chains. In addition, human constant heavy chains are usually divided into μ, δ, γ, α or ε, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA and IgE, respectively. The subtypes of these IgGs include, for example, IgG1 and IgG4.
[0156] As used herein, "variable region", "variable domain", "V region" or "V chain" means the segment of the IgG chain whose sequence varies between different antibodies. The "variable region" of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, alone or in combination. The variable region of the heavy chain may be referred to as "V.sub.H". The variable region of the light chain may be referred to as "V.sub.L". Typically, the variable regions of both the heavy and light chains include three hypervariable regions, also referred to as complementarity determining regions (CDRs), which are located within relatively conserved framework regions (FRs). CDRs are typically aligned by the framework regions to enable binding to specific epitopes. In general, from N-terminus to C-terminus, both the light and heavy chain variable domains include FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is generally based on the following definitions: Sequences of Proteins of Immunological Interest, Kabat et al.; National Institutes of Health, Bethesda, Md.; 5th Edition; NIH Publication No. 91-3242 (1991); Kabat (1978) Adv. Prot. Chem. 32: 1-75; Kabat et al., (1977) J. Biol. Chem. 252: 6609-6616; Chothia et al., (1987) J. Molecular Biology 196: 901-917 or Chothia et al., (1989) Nature 342: 878-883.
[0157] "CDR" refers to one of the three hypervariable regions (H1, H2 or H3) in the non-framework region of the antibody V.sub.H.β-sheet framework, or one of the three hypervariable regions (L1, L2 or L3) in the non-framework region of the antibody V.sub.L.β-sheet framework. Therefore, CDR is a variable region sequence interspersed within the framework region sequence. CDR regions are well known to those skilled in the art and have been defined, for example, by Kabat as regions with the greatest hypervariability within the variable domain of an antibody. CDR region sequences have also been structurally defined by Chothia as those residues that are not part of the conserved .β-sheet framework and are therefore able to adapt to different conformations. Both terms are recognized in the art. CDR region sequences have also been defined by AbM, Contact and IMGT. The position of CDRs in typical antibody variable regions has been determined by comparison of many structures (Al-Lazikani et al., 1997, Journal of Mol. Biol. 273:927-48; Morea et al., 2000, Methods 20:267-79). Because the number of residues in the hypervariable region is different in different antibodies, in the typical variable region numbering scheme (Al-Lazikani et al., supra), additional residues relative to the typical position are usually numbered with a, b, c, etc. next to the residue number. Such nomenclature is also well known to those skilled in the art. The corresponding relationship between numbering systems (including, for example, Kabat numbering and IMGT unique numbering system) is well known to those skilled in the art. In some embodiments, CDRs are as defined by the Kabat numbering system. In other embodiments, CDRs are as defined by the IMGT numbering system. In other embodiments, CDRs are as defined by the AbM numbering system. In still other embodiments, CDRs are as defined by the Chothia numbering system. In yet other embodiments, CDRs are as defined by the Contact numbering system. In Table 2, sequences are listed using the IMGT nomenclature.
[0158] Sequence identity refers to the extent to which the amino acids in two polypeptides are identical at equivalent positions when the two sequences are optimally aligned.
[0159] Sequence similarity encompasses identical residues and non-identical biochemically related amino acids. Biochemically related amino acids that share similar properties and are interchangeable are discussed above.
[0160] "Conservatively modified variants" or "conservative substitutions" refer to the use of other amino acids with similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, main chain conformation and rigidity, etc.) to replace amino acids in proteins, so that such changes can generally be made without changing the biological activity of the protein. Those skilled in the art recognize that, in general, single amino acid substitutions in non-essential regions of polypeptides will not substantially change biological activity (see, e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224 (4th ed.)). In addition, substitutions of amino acids that are similar in structure or function are unlikely to destroy biological activity.
[0161] As used herein, the term "epitope" refers to a region or area on an antigen to which an antibody or antigen-binding fragment binds. The binding of an antibody or antigen-binding fragment thereof disclosed herein to an epitope means that the antibody or antigen-binding fragment thereof binds to one or more amino acid residues within the epitope.
[0162] By "isolated" nucleic acid molecule or polynucleotide is meant a DNA or RNA (e.g., genomic), mRNA, cDNA, or synthetic origin, or some combination thereof, which is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, or is linked to a polynucleotide to which it is not linked in nature. For purposes of this disclosure, it is understood that a "polynucleotide" that "comprising" (or similar terms) a particular nucleotide sequence does not encompass an entire chromosome. In addition to the specified sequence, an isolated polynucleotide that "comprising" a particular nucleic acid sequence may contain coding sequences for up to ten or even up to twenty or more other proteins or portions or fragments thereof, or may contain operably linked regulatory sequences that control expression of the coding region of the recited nucleic acid sequence, and / or may contain vector sequences.
[0163] The phrase "control sequence" refers to a polynucleotide sequence that is necessary for or contributes to the expression of an operably linked coding sequence in a specific host organism. Control sequences suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to use promoters, polyadenylation signals, and enhancers. In an embodiment of the present invention, the polynucleotide is operably linked to a promoter, such as a viral promoter, a CMV promoter, a SV40 promoter, or a non-viral promoter or an elongation factor (EF)-1 promoter; and / or an intron.
[0164] A nucleic acid is "operably linked" when it is in a functional relationship with another polynucleotide. For example, if it is expressed as a preprotein that participates in the secretion of a polypeptide, the DNA of a presequence or secretory leader is operably linked to the DNA of a polypeptide; if it affects the transcription of a sequence, a promoter or enhancer is operably linked to a coding sequence; or if it is positioned to facilitate translation, a ribosome binding site is operably linked to a coding sequence. Usually, but not always, "operably linked" means that the polynucleotide sequences connected are continuous, and in the case of a secretory leader, they are continuous and in the reading phase. However, enhancers do not have to be continuous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adapters or linkers are used according to conventional practice.
[0165] As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably, and all such names include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, regardless of the number of transfers. It is also understood that not all progeny have exactly the same DNA content, due to intentional or unintentional mutations. Mutant progeny having the same function or biological activity as the original transformed cell from which it was selected are included. If a different name is intended, it should be clear from the context.
[0166] Host cells include eukaryotic and prokaryotic host cells, including mammalian cells. Among others, host cells include Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, and HEK-293 cells. Mammalian host cells include humans, mice, rats, dogs, monkeys, pigs, goats, cattle, horses, and hamster cells. Other cell lines that can be used include insect cell lines (e.g., Spodoptera frugiperda or Trichoplusia ni), amphibian cells, bacterial cells, plant cells, and fungal cells.Fungal cells include yeast and filamentous fungal cells, including, for example, Pichia pastoris, Pichia finlandica, Pichia trehalophia, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataeaminuta, Pichia lindnen), Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia sp., Saccharomyces cerevisiae, Saccharomyces sp., Hansenula polymorpha, Kluyveromyces sp., Kluyveromyces lactis, Candida albicans, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Chrysosporium lucknowense, Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens, and Neurospora crassa. Pichia, any Saccharomyces, Hansenula polymorpha, any Kluyveromyces, Candida albicans, any Aspergillus, Trichoderma reesei, Chrysosporium lukenovensi, any Fusarium, Yarrowia lipolytica, and Neurospora crassa.The present invention encompasses any host cell (eg, a CHO cell or a Pichia cell, such as Pichia pastoris) containing an anti-ILT4 antibody or antigen-binding fragment thereof, or containing a polynucleotide encoding such an antibody or fragment, or containing a vector comprising the polynucleotide.
[0167] "Treatment" means administering an antibody or antigen-binding fragment thereof of the present invention to a subject having one or more symptoms of a disease, the antibody and antigen-binding fragment being effective for the disease, for example, in treating a subject with cancer or an infectious disease, or in treating a subject suspected of having cancer or an infectious disease, the agent having therapeutic activity therefor. Typically, an antibody or fragment is administered in an "effective amount" or "effective dose" that will alleviate one or more symptoms (e.g., symptoms of cancer or an infectious disease) in the treated subject or population, either by inducing regression or elimination of such symptoms, or by inhibiting the progression of such symptoms (e.g., inhibiting cancer symptoms, such as tumor growth or metastasis, to any clinically measurable degree). The effective amount of an antibody or fragment may vary according to factors such as the stage of the disease, age, and weight of the patient, and the ability of the drug to elicit a desired response in the subject.
[0168] Examples
[0169] Example 1: Phage display screening of GPC3 FVS using a human scFV library containing fixed variable heavy chain domains
[0170] Vaughan et al. describe a general procedure for the construction and processing of human scFv libraries displayed on M13 phage (Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library). Vaughan, T. et al. Nat Biotechnol 14, 309-314 (1996), which is hereby incorporated by reference in its entirety. The libraries used for selection and screening encode scFvs that all share the same VH domain and are diversified only in the VL domain. Different VH domains were used to identify libraries of GPC3 binders for GPC3xCD3 bispecific antibodies on the one hand and GPC3 binders for GPC3xCD28 on the other hand. US 2012 / 0184716 and WO Methods for generating fixed VH libraries and their use for identifying and assembling bispecific antibodies are described in 2012 / 023053, each of which is hereby incorporated by reference in its entirety. The procedure for identifying scFv binding to human GPC3 (huGPC3) is described below. Selection is performed in a solution with biotinylated huGPC3 protein and / or on cells expressing huGPC3. The selection strategy comprises up to 4 rounds of selection: (i) against recombinant protein, (ii) 2 rounds against recombinant protein followed by 2 rounds against cells.
[0171] Protein selection
[0172] An aliquot of the scFv phage library was blocked with PBS containing 2% (w / v) skim milk. First, the scFv phage library was cloned into streptavidin / neutravidin magnetic beads (Dynabeads TM MyOne TM Streptavidin T1 magnetic beads or Sera-Mag SpeedBeadsNeutravidin TM The blocked phages were deselected on magnetic beads (coated magnetic particles) and then pre-incubated with 100 nM, 50 nM or 5 nM of biotinylated recombinant human GPC3 (GP3-H82E5 AcroBiosystems or produced in-house). The phage + antigen mixture was then captured by blocked magnetic beads (same species used for deselection) and washed with PBS / 0.1% 20 washing five times, and only washed twice with PBS. Phage was eluted with 1mg / mL trypsin, and after adding AEBSF to block trypsin activity, it was directly added to TG1 cells growing exponentially. Serial dilutions of infected TG1 were selected for output with titration. Then the output was recovered and used for the next round of selection.
[0173] Example 2: Phage display screening of CD28 FVS using a human scFV library containing fixed variable heavy chain domains
[0174] The general procedure for constructing and processing a human scFv library displayed on M13 phage is the same as described above. The procedure for identifying scFv binding to human CD28 (huCD28) is as follows. Selections were performed in a solution with biotinylated huCD28 protein and / or on cells expressing huCD28. The selection strategy comprised up to 4 rounds of selection: (i) for recombinant protein, (ii) alternating recombinant protein and cells, (iii) 2 rounds for recombinant protein followed by 2 rounds for cells.
[0175] Protein selection
[0176] An aliquot of the scFv phage library was blocked with PBS containing 2% (w / v) skim milk. First, the scFv phage library was cloned into streptavidin / neutravidin magnetic beads (Dynabeads TM MyOne TM Streptavidin T1 magnetic beads or Sera-Mag SpeedBeadsNeutravidin TM The blocked phages were deselected on magnetic particles (coated with magnetic particles) and then pre-incubated with 200nM, 100nM, 50nM or 5nM of biotinylated recombinant human CD28 (CD8-H82E5, Biopsies Biotech). The phage + antigen mixture was then captured by blocked magnetic beads (same species used for deselection) and washed with PBS / 0.1% 20 washing five times, and only washed twice with PBS. Phage was eluted with 1mg / mL trypsin, and after adding AEBSF to block trypsin activity, it was directly added to TG1 cells growing exponentially. Serial dilutions of infected TG1 were selected for output with titration. Then the output was recovered and used for the next round of selection.
[0177] Cell surface selection
[0178] The supernatant containing phage is sealed with PBS containing 10% FBS. First, the blocked phage is deselected on CD28 negative TIB-153 cells (ATCC TIB 153), and then selected on CD28 positive Jurkat cells (Jurkat clone E6-1, ATCC TIB 152). The cells are precipitated and washed five times with PBS containing 10% FBS, and then only washed once with PBS. The phage is eluted with 1mg / mL trypsin, and after adding AEBSF to seal the trypsin activity, it is directly added to the TG1 cells growing exponentially. The aliquots of TG1 infected by serial dilution are selected with titration output. The output is then recovered and used for the next round of selection.
[0179] Example 3: Screening for SCFVs that bind / do not bind to human GPC3
[0180] Screening for scFv binding to GPC3 was tested by ELISA using biotinylated huGPC3-His (or biotinylated irrelevant protein huMSLN as negative control) or by flow cytometry using GPC3 positive (Hep G2) and GPC3 negative (SK-HEP-1) cells.
[0181] ELISA
[0182] For binding ELISA, neutravidin coated plates were blocked with PBS containing 1% casein. Biotinylated huGPC3-His and biotinylated huMSLN (mesothelin) were captured at 5nM. Dilutions of freshly prepared periplasmic extracts containing the selected scFv were applied to the plates and detected using a combination of mouse anti-c-myc antibody and donkey anti-mouse IgG HRP antibody. The OD at 450nm generated after the addition of TMB was measured using a microplate spectrophotometer. If the hit failed to bind to the unrelated huMSLN protein and if the OD450 on huCD28 was at least 3 times higher than the background OD450, the hit was classified as a specific binder.
[0183] Flow cytometry
[0184] For flow cytometry binding assays, cells were harvested, washed and dispensed into V-bottom 96-well plates at 150'000 or 200'000 cells / well. Dilutions of freshly prepared periplasmic extracts containing the selected scFv were pre-incubated with mouse anti-c-myc antibody and added to the cells. After incubation, cells were washed, incubated with goat anti-mouse IgG-APC detection antibody and analyzed in an iQUE3 screening device (Sartorious). Hits were classified as positive and specific if at least 5% of the cells showed a binding signal 3 times greater than the GeoMFI of the background on Hep G2 (ATCC HB-8065) cells and if no such signal was observed on SK-HEP-1 (ATCC HTB-52) cells.
[0185] Positive and specific hits were sequenced after DNA extraction from individual clones.
[0186] Example 4: Screening for SCFVs that bind / do not bind to human CD28
[0187] Screening for scFv binding to CD28 was tested by ELISA using biotinylated huCD28-His (or biotinylated huCEA_ECD as a negative control) or by flow cytometry using CD28 positive (Jurkat) and CD28 negative (TIB-153) cells.
[0188] ELISA
[0189] A similar approach was used to perform anti-GPC3 scFv screening as described above. Instead of using recombinant huGPC3, biotinylated huCD28-His and biotinylated huCEA_ECD were captured at 5 nM on neutravidin coated plates.
[0190] Flow cytometry
[0191] Anti-GPC3 scFv screening was performed using a similar approach as described above. Jurkat cells and TIB-153 cells were used as CD28 positive and CD28 negative cells, respectively.
[0192] Example 5: Fixed VH candidates reformatted to IGG and transiently expressed in mammalian cells
[0193] After screening and sequencing, scFv candidates with the desired binding properties were reformatted into IgG and expressed by transient transfection into PEAK cells. The VH and VL sequences of the selected scFv were amplified with specific oligonucleotides and cloned into expression vectors containing heavy and light chain constant regions. The expression vector was verified by sequencing and transfected into mammalian cells using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. In brief, 4x106 PEAK cells were cultured in 25mL of culture medium containing fetal bovine serum in a T75 flask. The transfected cells were cultured at 37°C for 5-6 days, and the production of IgG was quantified using an Octet RED96 instrument. The supernatant was harvested and IgG purification was performed on FcXL affinity resin (Thermo Fisher Scientific) according to the manufacturer's instructions. In brief, the supernatant from the transfected cells was incubated overnight at 4°C with an appropriate amount of FcXL resin. After washing the resin with PBS, the sample was loaded onto an Amicon Pro post, and IgG was then eluted in 50 mM glycine (pH 3.5). The eluted IgG fraction was then dialyzed against histidine NaCl pH 6.0 buffer with an Amicon 50 kDa and quantitatively analyzed by the absorption at 280 nm. Purity and IgG integrity were verified by electrophoresis using an Agilent Bioanalyzer 2100 according to the manufacturer's instructions (Agilent Technologies).
[0194] Example 6: Anti-GPC3 M A B Binding to GPC3-positive cells
[0195] The binding capacity of the anti-GPC3 antibody arms of the invention tested as bivalent mAbs is assessed by flow cytometry using, for example, Hep G2, Hep 3B or SK-HEP-1 cells.
[0196] Cells were harvested, checked for viability and counted. 200'000 cells were incubated at 4°C with increasing concentrations of antibodies diluted in FACS buffer (PBS 2% BSA) for 15 minutes. The cells were washed twice with cold FACS buffer and incubated with the appropriate anti-human IgG secondary antibody for another 15 minutes at 4°C. The cells were washed twice with cold FACS buffer and resuspended in 150 μl FACS buffer with a compatible viability marker. The binding of antibodies to live cells was measured by flow cytometry using the Cytoflex platform (Beckman Coulter). FlowJo TMData were analyzed using BD Biosciences v10 software (BD Life Sciences), and dose response binding curves were plotted using GraphPad Prism 9 software. The AD84 GPC3 arm of the GPC3xCD3 bispecific antibody of the present invention and the P44, P30, P111 GPC3 arms of the GPC3xCD28 bispecific antibody were selected from this screening process based on their specificity and binding signal strength to GPC3-positive cells.
[0197] Example 7: Anti-CD28 M A B Binding to CD28-positive cells
[0198] The binding capacity of the anti-CD28 antibody arms of the present invention tested as bivalent mAbs was evaluated by flow cytometry using Jurkat cells (Jurkat clone E6-1, ATCC TIB 152). The flow cytometry method was the same as described above. The AI3 and AI10 CD28 binding arms were selected from this screening process based on their specificity and binding signal intensity to CD28 positive cells.
[0199] Example 8: Expression and purification of bispecific antibodies carrying λ and κ light chains
[0200] The simultaneous expression of one heavy chain and two light chains in the same cell can result in the assembly of three different antibodies. Simultaneous expression can be achieved in different ways, such as transfection of multiple vectors expressing one of the chains to be co-expressed or by using vectors driving the expression of multiple genes.
[0201] Here, two light chains are cloned into the previously generated vector pNoviκHλ to allow co-expression of one heavy chain, one κ light chain and one λ light chain, as described in US20120184716 and WO2012023053, each of which is hereby incorporated by reference in its entirety. The expression of these three genes is driven by the human cytomegalovirus promoter (hCMV), and the vector also contains a glutamine synthetase gene (GS), which enables selection and establishment of stable cell lines. The common VH and VL genes of anti-CD3 IgG (L3-1 / N) and anti-GPC3 IgG (AD84) or anti-CD28 IgG (AI3 or AI10) and anti-GPC3 (P44, P30 or P111) IgG are cloned in the vector pNoviκHλ for transient expression in mammalian cells. Expi293 cells are suspended in appropriate conical flasks with a suitable number of cells and medium volume. Plasmid DNA was transfected into Expi293 cells using PEI. The antibody concentration in the supernatant of transfected cells was measured during production using Octet RED96. Depending on the antibody concentration, the supernatant was harvested 5 to 7 days after transfection and clarified by filtration after adding diatomaceous earth (Sartorius). Purification was based on a three-step purification process. First, the CaptureSelect TM FcXL affinity matrix (Thermo Fisher Scientific) was then added to the clarified supernatant. After incubation overnight at +4°C and 20 rpm, the supernatant was centrifuged at 2000g for 10 minutes, the flow through was stored, and the resin was washed twice with PBS. The resin was then transferred to an Amicon Pro column and eluted using a solution containing 50 mM glycine at pH 3.5. Several elution fractions were generated, neutralized with Tris-HCl pH 7.4 and combined. The pool containing total human IgG (bispecific antibody and two monospecific antibodies) was quantified using a Nanodrop spectrophotometer (NanoDrop Technologies). A small portion of the sample was stored for further analysis, and the remaining sample was mixed with an appropriate volume of CaptureSelect TM The cells were incubated with KappaXL affinity matrix (Thermo Fisher Scientific) for 30 minutes. Resin recovery and washing, elution, and neutralization steps were performed as described above. TM The final affinity purification step was performed using the same procedure as for the κ purification step using the λFab affinity matrix (Thermo Fisher Scientific). Alternatively, purification was based on a two-step purification process in which only the CaptureSelect TMKappaXL Affinity Matrix and CaptureSelect TM Lambda Fab affinity matrix. All elution fractions were pooled and desalted using a 50 kDa Amicon Ultra centrifugal filter unit (Merck Millipore) with His-NaCl pH 6.0 formulation buffer. The final product was quantified using Nanodrop.
[0202] Purified bispecific antibodies were analyzed by electrophoresis under denaturing and reducing conditions using an Agilent 2100 bioanalyzer and a Protein 80 kit as described by the manufacturer (Agilent Technologies). Aggregation levels were determined by SEC-UPLC. All samples were tested for endotoxin contamination using the Limulus amebocyte lysate assay (LAL; Charles River Laboratories).
[0203] Example 9: In vitro characterization of bispecific antibodies
[0204] Binding of GPC3xCD3 bispecific antibody to GPC3-positive Hep G2 cells, CD3-positive Jurkat cells, and GPC3-negative / CD3-negative SK-HEP-1 cells
[0205] To demonstrate the binding of GPC3xCD3κλ bodies (e.g., AD84L3-1 / N) to target cells, a series of experiments based on flow cytometry were performed. Cell staining and binding assessment were performed as described in Example 6. GPC3-positive Hep G2 ( Figure 1A )、CD3 positive Jurkat( Figure 1B ) and GPC3-negative / CD3-negative SK-HEP-1 cells ( Figure 1C ) to obtain the binding curve. hIgG1 represents an irrelevant monoclonal antibody of hIgG1 Fc used as an isotype control. ERY974 described in WO2017 / 159287A1 was used as a reference comparator.
[0206] The bispecific binding ability of AD84L3-1 / N was confirmed by flow cytometry using cells expressing GPC3 or CD3 antigen ( Figure 1A and Figure 1B ). Figure 1A and Figure 1B The results in the results confirmed that ERY974 showed higher maximum binding activity to both Hep G2 and Jurkat cells. No binding was observed to non-expressing GPC3 and CD3 cells (SK-HEP-1) for both AD84L3-1 / N and ERY974 ( Figure 1C ).
[0207] Binding of GPC3xCD28 bispecific antibody to GPC3-positive FU97 cells, CD28-positive Jurkat cells, and GPC3-negative / CD28-negative TIB-153 cells
[0208] In order to demonstrate the binding of GPC3xCD28κλ bodies (AI3P44 / N and AI3P30 / N) to target cells, a series of experiments based on flow cytometry were performed. Examples of cells that can be used include GPC3 positive cell lines such as gastric cancer cell line FU97 (JCRB1074), CD28 positive cell lines such as leukemia Jurkat T cells, and GPC3 / CD28 double negative cell lines such as leukemia TIB-153 cells. Cell staining and binding assessment were performed as described in Example 6. The resulting binding curves are shown in Figure 6. Figure 2A-2C An irrelevant hIgG1 mAb was used as a negative isotype control and was used for comparison in all experiments shown. Binding data on FU97 cells ( Figure 2A ) emphasizes the range of binding affinities of huGPC3 of the selected anti-GPC3 arms P44 and P30 of the invention. Both the P44 and P30 arms bind to the membrane distal domain within GPC3. Binding on CD3-positive Jurkat cells highlights how these two CD28xGPC3 bispecific antibodies sharing the same anti-CD28 arm (e.g., AI3) bind similarly to CD28-positive cells ( Figure 2B The absence of binding signals on the GPC3 / CD28 negative TIB-153 cell line indicates that all binding arms of the present invention are specific for the designated target ( Figure 2C ).
[0209] Example 10: T cell-dependent cytotoxicity (TDCC) mediated by bispecific antibodies
[0210] Once co-engagement of each bispecific antibody was confirmed, the ability of the GPC3xCD3 and GPC3xCD28 bispecific antibody combinations to kill tumor cells in the presence of PBMC effector cells was tested using a panel of GPC3-positive malignant cells.
[0211] Human peripheral blood mononuclear cells PBMCs were used as effector cells to evaluate T cell-dependent cellular cytotoxicity (TDCC) of GPC3-positive and -negative tumor cell lines induced by the GPC3xCD3 bispecific antibodies tested alone or in combination with the GPC3xCD28 bispecific antibodies of the invention. At least 3 different donors were used in each experiment.
[0212] After washing twice with PBS, target cells were detached with cell dissociation solution. After a centrifugation step, cells were resuspended in assay medium, adjusted to the desired concentration, and plated in 96-well plates.
[0213] Using SepMate TM Tube (Stemcell Technologies) with Lymphoprep TM PBMCs were isolated from buffy coats derived from healthy human donors using ELISA buffer (Stem Cell Technologies, Inc.).
[0214] For the TDCC assay, PBMCs were added to target cells at a final E:T ratio of 20:1 (Engineering bispecific antibodies with a common light chain: Identification and optimization of anti-CD3ε and anti-GPC3 bispecific antibodies ERY974. Shiraiwa et al., Methods, 2018). A dose range of GPC3xCD3 and a fixed dose of GPC3xCD28 antibodies of the present invention (0.5, 0.1, 0.05 or 0.025 μg / mL, unless otherwise stated) were added to pre-plated target cells and effector cells. Alternatively, a non-targeting CD3 bispecific antibody (Y4L3-1 / N) was used instead of GPC3xCD3 (AD84L3-1 / N). hIgG1 was used as an isotype control. ERY974 single-agent treatment was used as a reference comparator. After incubation for 48 hours at 37°C, 5% CO2, target cell killing was assessed by quantifying LDH released into the culture medium by apoptotic / necrotic cells (Cytotoxicity Detection Kit PLUS (LDH), Roche). Maximum LDH release (=100% lysis) was obtained by incubating target cells with the lysis solution provided by the kit. Spontaneous LDH release (=0% lysis) refers to target cells co-incubated with effector cells without adding any antibodies. TDCC curves were drawn using GraphPad Prism 9. TDCC data are presented in Figures 3 to 6. EC50 (half-maximal concentration mediating killing) and Emax (maximum percentage of killing within the tested dose range) were determined using GraphPad Prism software. EC50 and Emax values were summarized using Hep G2 (Table 5A) or Hep 3B (Table 5B) target cells and 2 PBMC donors as the source of effector cells. Figures 10A-10F Demonstrated the use of Promega (G7570) Target cell killing was assessed by quantifying the remaining number of viable adherent cells in culture after 72 hours and comparing the values obtained in each treated well with the reference, i.e., untreated wells (=0% killing).
[0215] TDCC with HepG2 or Hep3B
[0216] In the dose range tested, CD3 and CD28 bispecific antibody combination therapy showed increased potency (lower EC50) and maximum killing (Emax) in killing of GPC3-expressing cancer cell lines Hep G2 (Table 5A) and Hep 3B (Table 5B) compared to GPC3xCD3 bispecific antibody as a single agent treatment. EC50 and Emax range values are from two representative PBMC donors used as a source of effector cells.
[0217] Table 5A - TDCC in Hep G2 cells
[0218] Ab EC50(ng / mL)* Emax (maximum damage %)* AD84L3-1 / N single ttt 200-600 3-5 +AI3P44 / N at 500 ng / mL 2-4 40-45 +AI3P44 / N at 100 ng / mL 6-10 30-35 +AI3P44 / N at 50 ng / mL 20-30 12-14 +AI3P44 / N at 25 ng / mL 150-200 5-6
[0219] Table 5B - TDCC in Hep 3B cells
[0220]
[0221]
[0222] *Across the dose range tested
[0223] The tested GPC3xCD28 bispecific antibody (e.g. AI3P44 / N) synergized with the GPC3xCD3 bispecific antibody of the invention (e.g. AD84L3-1 / N) to kill GPC3-positive Hep G2 target cells expressing 700'000 GPC3 / cell. Killing induced by two different PBMC donors was Figure 3A-3B 5A. Compared to AD84L3-1 / N monotherapy, synergy of the combination can be observed with lower EC50 and higher overall killing at the maximum concentration tested. Importantly, the dosage of the GPC3xCD28 bispecific antibody can be adapted to better control the synergistic effect (see also Table 5A). The combination of AD84L3-1 / N GPC3xCD3 with 100 ng / mL to 500 ng / mL AI3P44 / N was at least as good as ERY974 monotherapy ( Figure 3A-3B ). The GPC3-negative cell line SK-HEP-1 was not killed by any treatment, demonstrating the importance of engaging GPC3 to mediate TDCC ( Figure 3C-3D ).
[0224] The ability of GPC3xCD28 bispecific antibodies (e.g., AI3P44 / N) to enhance killing of tumor cells expressing GPC3 in the presence of GPC3xCD3 bispecific antibodies was tested and compared to other GPC3xCD28 bispecific antibodies of the present invention. These CD28 bispecific antibodies share the same CD28 arm (e.g., AI3), but are paired with different GPC3 arms, P30 or P111. The GPC3 arms P44 and P30 target membrane distal regions within GPC3. The P111 GPC3 arm binds proximally to the membrane like AD84L3-1 / N, and does not compete with the GPC3 arm of the CD3 bispecific antibody for binding to GPC3. In addition, the P44 and P30 arms do not compete with the GPC3 arm of the CD3 bispecific antibody. The resulting CD28 bispecific antibodies were tested under the same conditions as in Figure 3. The combinations of AD84L3-1 / N with AI3P44 / N, AI3P30 / N, and AI3P111 / N were tested at Figures 4A-4C Using GPC3-positive Hep G2 target cells, the data showed that synergistic TDCC was observed regardless of the GPC3xCD28 bispecific antibody used in the combination. The killing activity can be fine-tuned by reducing the concentration of each GPC3xCD28 bispecific antibody ( Figures 4A-4C When tested at the highest concentration (0.5 or 0.1 m / mL), ERY974, included as a reference, showed maximal killing equivalent to the CD28 bispecific antibody κλ body, with the exception of the candidate AI3P111 / N tested in the combination ( Figure 4C ), which is the same as AI3P44 / N( Figure 4A ) or AI3P30 / N( Figure 4B ) combination consistently produced weaker activity in vitro compared to the combination of GPC3xCD28κλ and GPC3xCD3κλ (AD84L3-1 / N). Overall, the data presented in the present invention indicate that GPC3xCD28κλ can increase GPC3xCD3κλ (AD84L3-1 / N) TDCC to levels similar to or higher than ERY974 monotherapy. The resulting TDCC activity can be attenuated by reducing the CD28κλ concentration or by using another GPC3 arm (e.g., P111, proximal to the GPC3 membrane). Importantly, if GPC3xCD3 is replaced by Y4L3-1 / N (a non-targeted CD3 bispecific antibody that cannot deliver signal 1 to T cells), none of the CD28 bispecific antibodies included in the combination induce killing, which emphasizes the importance of primary T cell stimulation (signal 1) to the activity of CD28 bispecific antibodies ( Figures 4A-4C ).
[0225] Another set of TDCC experiments was performed to evaluate the effect of a lower anti-CD28 arm (e.g., AI10) on TDCC activity when paired with one of the GPC3 binding arms of the invention (e.g., P44). The data showed that both CD28 bispecific antibodies (AI3P44 / N and AI10P44 / N) bound similarly to GPC3-positive cells, with all P44-containing antibodies showing equivalent dose range curves ( Figure 5A ). The data showing the binding range of the bispecific antibody containing AI3 showed that the binding signal on CD28-positive cells (Jurkat) was higher compared to the bispecific antibody containing AI10 ( Figure 5B ). This data suggests that the CD28 AI10 binding arm has lower binding affinity compared to the AI3 binding arm. The antibody combinations were then tested using the optimized dose ranges previously fixed. Using the GPC3-expressing cell line Hep G2, the TDCC data suggest that activity reflects the affinity of the CD28 arm. At moderate concentrations of GPC3xCD28κλ bodies, higher TDCC activity was observed for the AI3P44 / N combination compared to the AI10P44 / N combination (10.3% and 10.7%, respectively). Figure 5C and 5D However, increasing the concentration of low-affinity CD28 bispecific antibodies (e.g., AI10P44 / N) can further enhance the synergistic killing activity to levels above that of ERY974 monotherapy ( Figure 5D ).
[0226] To further evaluate the killing synergy, a GPC3 cell line with lower target expression was included. The synergy between the CD3 bispecific antibody and the CD28 bispecific antibody is not cell line specific, because the CD3 and CD28 bispecific antibody combination also kills the Hep 3B cell line (expressing 60'000 GPC3 / cell, ATCC Hep3B2.1-7) more efficiently than the GPC3xCD3 bispecific antibody alone. It was found that the killing of all CD28 bispecific antibodies claimed in this application increased. The combination of AD84L3-1 / N and AI3P30 / N at 2.5 μg / mL showed similar or slightly lower killing than ERY974 monotherapy ( Fig. 6A ).like Figure 6B , 6C As shown in Figures 6 and 6D, effector cells from three independent PBMC donors all induced superior killing with 0.5 μg / mL of AI3P44 / N compared to ERY974 alone. As observed in HepG2 cells, the synergistic killing activity of Hep 3 B cells could also be fine-tuned by decreasing the concentration of the GPC3xCD28 bispecific antibody ( Figure 6B-6D, Table 5B). Combining the CD3 bispecific antibody with the CD28 bispecific antibody, pairing the low affinity CD28 arm (AI10) with the GPC3 arm (P44), also enhanced Hep 3B cell killing compared to the CD3 bispecific antibody alone. In this case, efficacy was comparable to ERY974 monotherapy ( Fig. 6E ).
[0227] Example 11: Enhanced cytokine release in the supernatant after killing of GPC3-expressing tumor cells by co-stimulation of CD28 and GPC3×CD28 bispecific antibodies
[0228] In clinical trials, ERY974 monotherapy was shown to induce severe cytokine release syndrome (CRS). Such CRS can be driven by excessive activation of T cells. In fact, T cell activation leads to the release of effector cytokines, which may compromise the therapeutic window in patients.
[0229] The ability of the CD28 bispecific antibodies of the invention to enhance the release of cytokines by T cells following killing of GPC3-expressing tumor cells in the presence of GPC3xCD3 was assessed by quantifying selected cytokines in the supernatant at the end of the TDCC assay. Cytokine levels were compared to those induced by ERY974 monotherapy.
[0230] After co-culturing GPC3-positive target cells with PBMCs containing T cells as described in Example 10, the culture supernatant was harvested by centrifugation and stored frozen at -80° until further analysis. Cytokines (IL-2, IL-6, TNF-α, and IFN-γ) were quantified using the Mesoscale Discovery platform using multiplex kits.
[0231] The results of the experiment in which Hep G2 cells were co-cultured with PBMCs at an E:T ratio of 20:1 for 48 hours under a certain dose range of GPC3xCD3 and different fixed doses of GPC3xCD28 bispecific antibody (AI3P44 / N) showed that the Figures 7A-7D The obtained TDCC is shown in Fig. 7A The levels of IFN-g, IL-6 and TNF-a were shown in Figure 7B , Figure 7C and Fig.7DDepicted in Figure 4. Single-agent treatment with GPC3xCD3 (AD84L3-1 / N) resulted in very low levels of cytokine release by T cells, whereas combination treatment with the GPC3xCD28 bispecific antibody tested substantially increased all measured cytokines, reflecting better activation of T cells as indicated by increased TDCC activity as previously described. By reducing the concentration of the CD28 bispecific antibody, the resulting cytokine levels could be reduced to levels below those obtained with ERY974 monotherapy, and importantly, without statistically significantly compromising the maximal killing activity provided by the combination ( Figures 7A-7D ).like Figures 7A-7D As shown, at 0.1 mg / mL, the maximum AI3P44 / N killing / TDCC was higher than that achieved with ERY974; however, the release of IFN-g, IL-6, and TNF-a was lower than that observed with ERY974. Similar data were generated by using another CD28 bispecific antibody that paired the same CD28 arm (e.g., AI3) with another GPC3 arm (e.g., P30).
[0232] Both cytotoxic activity and cytokine release can be fine-tuned by reducing the concentration of the CD28 module ( Figures 8A-8D If the concentration of AI3P30 was reduced from 500 ng / mL to 100 or 50 ng / mL, the decrease in maximal killing was less than the reduction in cytokine release ( Figures 8A-8D ). At 0.5 mg / mL of AI3P30 / N, the maximum killing achieved was close to that achieved with ERY974, but cytokine release was lower, especially for IL-6 and TNF-a. Figures 9E-9H The data in show that the combination of AD84L3-1 / N and 100 ng / mL AI10P44 (the lower affinity CD28 arm) released much lower cytokines than ERY974 alone, but the maximum efficacy / killing of GPC3-expressing cancer cells was approximately 30% with ERY974 and still approximately 20% with the combination ( Figures 9E-9F ). The GPC3xCD3 and GPC3xCD28 bispecific antibodies of the present invention enable the ratio of tumor cell killing to cytokine release to be changed. This allows the ability to reduce CRS, which is superior to current therapies such as "ERY974", which fail to achieve clinical efficacy at low doses and induce high CRS (ERY974 anti-GPC3 / CD3 bispecific antibody Phase 1 dose escalation study results in patients with advanced solid tumors. Safran et al. Cancer Research (2021) 81(13_Suppl): CT111).
[0233] Finally, the combined TDCC activity is shown using the CellTiter-Glo reader. In contrast to the LDH release assay that relies on dead cells for TDCC quantification, the CellTiter-Glo assay format quantifies the ATP level in the remaining live cells, which better reflects the TDCC induced by the bispecific antibody in the presence of effector cells, and is considered to be more sensitive (Choosing the right cell-based assay for your research. Riss, T. et al. Promega Cell Note, Issue 6 (2003)). The concentration-dependent killing of three different cancer cell lines expressing GPC3 is shown, and the cancer cell line expresses GPC3 in large quantities, including HepG2 (700'000GPC3 / cell), Hep 3B (60'000GPC3 / cell) and HuH-7 (18'000GPC3 / cell). As observed in HepG2 cells, the combination of AD84L3-1 / N and AI3P44 / N (0.5 or 0.1 mg / mL) enhanced the killing of cancer cells by up to 80%, with an efficacy comparable to that of ERY974 monotherapy ( Figures 10A-10B A strong synergistic killing effect of the combination was also observed using Hep 3B cells (up to 80% of the maximum killing). Figures 10A-10F showed that the efficacy of the combination could even be driven to higher tumor cell killing potency than that achieved with ERY974 ( Figures 10C-10D Using HuH-7 cells, AI3P44 / N (tested at 0.5 mg / mL) could enhance AD84L3-1 / N-mediated killing / TDCC to levels approaching those of ERY974 monotherapy, with maximal killing of malignant cells of 60-80% ( Figures 10E-10F ).
[0234] In summary, the data in the present invention indicate that GPC3xCD28κλ body can enhance GPC3xCD3κλ body (AD84L3-1 / N)-mediated killing / TDCC to levels close to or above ERY974 single-agent treatment, particularly in tumor cells with low GPC3 expression. TDCC and related cytokine production can be attenuated while maintaining efficacy by reducing CD28κλ body concentration, CD28 affinity, or using another GPC3 arm (e.g., P30) or CD28 arm (e.g., AI10). In addition, at similar or equal efficacy / TDCC, cytokine release induced by the combination of the bispecific antibodies of the present invention was significantly lower when compared to ERY974 ( Figures 9A-9H ).
[0235] Other embodiments
[0236] While the invention has been described in conjunction with specific embodiments thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.
[0237] Additional embodiments of the present disclosure include the following:
[0238] Embodiment 1. A bispecific antibody comprising:
[0239] a. a first antigen binding domain, which binds to CD3; wherein the first antigen binding domain comprises:
[0240] i. a first heavy chain variable region, the first heavy chain variable region comprising: (SEQ ID NO:
[0241] 6); a complementary determining region 2 (CDR2) comprising the amino acid sequence of (SEQ ID NO: 7); and a complementary determining region 3 (CDR3) comprising the amino acid sequence of (SEQ ID NO: 8); and
[0242] ii. a first light chain variable region, the first light chain variable region comprising:
[0243] 1. A CDR1 comprising the amino acid sequence of SEQ ID NO: 11;
[0244] 12; and a CDR2 comprising the amino acid sequence of SEQ ID NO: 13; and
[0245] b. a second antigen binding domain that binds to GPC3, wherein the second antigen binding domain comprises:
[0246] i. a second heavy chain variable region, the second heavy chain variable region having: a CDR1 comprising the amino acid sequence of SEQ ID NO: 6; a CDR2 comprising the amino acid sequence of SEQ ID NO: 7; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 8; and
[0247] ii. a second light chain variable region, the second light chain variable region having:
[0248] 1. A CDR1 comprising the amino acid sequence of SEQ ID NO: 16; comprising SEQ ID NO:
[0249] and a CDR3 comprising the amino acid sequence of SEQ ID NO: 18; or
[0250] 2. A CDR1 comprising the amino acid sequence of SEQ ID NO: 21;
[0251] a CDR2 comprising the amino acid sequence of SEQ ID NO: 22; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 23.
[0252] Embodiment 2. A bispecific antibody comprising:
[0253] c. a first antigen binding domain that binds to CD28; wherein the first antigen binding domain comprises:
[0254] i. a first heavy chain variable region, the first heavy chain variable region comprising: (SEQ ID NO:
[0255] 1); a complementary determining region 2 (CDR2) comprising the amino acid sequence of (SEQ ID NO: 2); and a complementary determining region 3 (CDR3) comprising the amino acid sequence of (SEQ ID NO: 3); and
[0256] ii. a first light chain variable region, the first light chain variable region comprising:
[0257] 1. A CDR1 comprising the amino acid sequence of SEQ ID NO: 41; comprising SEQ ID NO:
[0258] and a CDR3 comprising the amino acid sequence of SEQ ID NO:43; or
[0259] 2. A CDR1 comprising the amino acid sequence of SEQ ID NO: 46; a CDR2 comprising the amino acid sequence of SEQ ID NO:
[0260] and a CDR3 comprising the amino acid sequence of SEQ ID NO:48; or
[0261] 3. A CDR1 comprising the amino acid sequence of SEQ ID NO: 51; comprising SEQ ID NO:
[0262] A CDR2 comprising the amino acid sequence of SEQ ID NO: 52; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 53;
[0263] d. a second antigen binding domain that binds to GPC3, wherein the second antigen binding domain comprises:
[0264] i. a second heavy chain variable region, the second heavy chain variable region having: a CDR1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and
[0265] ii. a second light chain variable region, the second light chain variable region having:
[0266] 1. A CDR1 comprising the amino acid sequence of SEQ ID NO: 26; comprising SEQ ID NO:
[0267] and a CDR3 comprising the amino acid sequence of SEQ ID NO: 28; or
[0268] 2. A CDR1 comprising the amino acid sequence of SEQ ID NO:31; a CDR2 comprising the amino acid sequence of SEQ ID NO:
[0269] and a CDR3 comprising the amino acid sequence of SEQ ID NO: 33; or
[0270] 3. A CDR1 comprising the amino acid sequence of SEQ ID NO:36; comprising SEQ ID NO:
[0271] a CDR2 comprising the amino acid sequence of SEQ ID NO: 37; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 38.
[0272] Embodiment 3. The bispecific antibody of claim 2, wherein the first heavy chain variable region and the second heavy chain variable region comprise the amino acid sequence of SEQ ID NO:4.
[0273] Embodiment 4. The bispecific antibody of claim 1, wherein the first heavy chain and the second heavy chain comprise the amino acid sequence of SEQ ID NO:9.
[0274] Embodiment 5. The bispecific antibody according to claim 2, wherein for the second light chain variable region
[0275] a. Part ii (1) comprises the amino acid sequence of SEQ ID NO: 29;
[0276] b. Part ii(2) comprises the amino acid sequence of SEQ ID NO:34; or
[0277] c. Part ii(3) includes the amino acid sequence of SEQ ID NO:39.
[0278] Embodiment 6. The bispecific antibody according to claim 1, wherein for the second light chain variable region
[0279] a. Part ii(1) comprises the amino acid sequence of SEQ ID NO:19; or
[0280] b. Part ii(2) includes the amino acid sequence of SEQ ID NO:24.
[0281] Embodiment 7. The bispecific antibody of claim 1, wherein the first light chain variable region comprises the amino acid sequence of SEQ ID NO:14.
[0282] Embodiment 8. The bispecific antibody of claim 1, wherein the first light chain comprises the amino acid sequence of SEQ ID NO:15.
[0283] Embodiment 9. The bispecific antibody according to claim 2, wherein for the first light chain variable region
[0284] a. Part a(ii)1 includes the amino acid sequence of SEQ ID NO:44;
[0285] b. part a(ii)2 comprises the amino acid sequence of SEQ ID NO:49; or
[0286] c. Part a(ii)2 includes the amino acid sequence of SEQ ID NO:54.
[0287] Embodiment 10. The bispecific antibody according to claim 2, wherein for the first light chain
[0288] a. Part a(ii)1 comprises the amino acid sequence of SEQ ID NO:45;
[0289] b. part a(ii)2 comprises the amino acid sequence of SEQ ID NO:50; or
[0290] c. Part a(ii)2 includes the amino acid sequence of SEQ ID NO:55.
[0291] Embodiment 11. The bispecific antibody according to any one of the preceding claims, wherein the first light chain is κ and the second light chain is λ.
[0292] Embodiment 12. The bispecific antibody according to any one of the preceding claims, wherein the first light chain is λ and the second light chain is κ.
[0293] Embodiment 13. The bispecific antibody according to any of the preceding claims, wherein the bispecific antibody comprises an Fc domain comprising one or more amino acid substitutions that reduce binding to an activating Fc receptor and / or reduce effector function.
[0294] Embodiment 14. The bispecific antibody of claim 13, wherein the amino acid substitutions comprise L234A and L235A substitutions.
[0295] Embodiment 15. The bispecific antibody according to claim 13 or 14, wherein the amino acid substitutions comprise L234A, L235A and P329A or P329G or P329R substitutions.
[0296] Embodiment 16. The bispecific antibody according to any one of the preceding claims, wherein said antibody has an IgG isotype.
[0297] Embodiment 17. The bispecific antibody according to any one of the preceding claims, wherein said antibody is a human antibody.
[0298] Embodiment 18. The bispecific antibody according to any one of the preceding claims, wherein the composition enables tumor-specific T cell activation.
[0299] Embodiment 19. A composition comprising the bispecific antibody according to any one of the preceding claims.
[0300] Embodiment 20. A composition comprising the bispecific antibody according to claim 1 and claim 2.
[0301] Embodiment 21. A method of reducing the proliferation of cancer cells and / or killing cancer cells, the method comprising contacting the cells with a composition according to any one of claims 19 to 20.
[0302] Embodiment 22. A method of treating cancer in a subject, the method comprising administering to the subject a composition according to any one of claims 19 to 20.
[0303] Embodiment 23. The method of claim 21 or 22, wherein the cancer is GPC3 positive.
Claims
1. A bispecific antibody comprising: a. a first antigen binding domain, which binds to CD3; wherein the first antigen binding domain comprises: i. a first heavy chain variable region, the first heavy chain variable region comprising: a complementary determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO: 6; a complementary determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO: 7; and a complementary determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO: 8; and ii. a first light chain variable region, the first light chain variable region comprising: CDRL1 comprising the amino acid sequence of SEQ ID NO: 11; CDRL2 comprising the amino acid sequence of SEQ ID NO: 12; and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 13; and b. a second antigen binding domain that binds to GPC3, wherein the second antigen binding domain comprises: i. a second heavy chain variable region, the second heavy chain variable region comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 6; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 7; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 8; and ii. a second light chain variable region, the second light chain variable region having:
1. CDRL1 comprising the amino acid sequence of SEQ ID NO: 16; CDRL2 comprising the amino acid sequence of SEQ ID NO: 17; and CDRL3 comprising the amino acid sequence of SEQ ID NO: 18; or 2. CDRL1 comprising the amino acid sequence of SEQ ID NO:21; CDRL2 comprising the amino acid sequence of SEQ ID NO:22; and CDRL3 comprising the amino acid sequence of SEQ ID NO:
23.
2. The bispecific antibody of claim 1, wherein the first heavy chain variable region and the second heavy chain variable region comprise the amino acid sequence of SEQ ID NO:
9. 3 . The bispecific antibody according to any one of claims 1 to 2 , wherein the first heavy chain and the second heavy chain comprise the amino acid sequence of SEQ ID NO:
10. 4 . The bispecific antibody according to any one of claims 1 to 3 , wherein the first light chain variable region comprises the amino acid sequence of SEQ ID NO:
14. 5 . The bispecific antibody according to any one of claims 1 to 4 , wherein the first light chain comprises the amino acid sequence of SEQ ID NO:
15.
6. The bispecific antibody according to any one of claims 1 to 5, wherein for the second light chain variable region a. part b.ii.
1. comprises the amino acid sequence of SEQ ID NO: 19; or b. Part b.ii.
2. includes the amino acid sequence of SEQ ID NO:
24.
7. The bispecific antibody according to any one of claims 1 to 6, wherein for the second light chain a. part b.ii.
1. comprises the amino acid sequence of SEQ ID NO:20; or b. Part b.ii.
2. includes the amino acid sequence of SEQ ID NO:
25.
8. A bispecific antibody comprising: a. a first antigen binding domain that binds to CD28; Wherein the first antigen binding domain comprises: i. a first heavy chain variable region, the first heavy chain variable region comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and ii. a first light chain variable region, the first light chain variable region comprising:
1. CDRL1 comprising the amino acid sequence of SEQ ID NO:41; CDRL2 comprising the amino acid sequence of SEQ ID NO:42; and CDRL3 comprising the amino acid sequence of SEQ ID NO:43; or 2. CDRL1 comprising the amino acid sequence of SEQ ID NO:46; CDRL2 comprising the amino acid sequence of SEQ ID NO:47; and CDRL3 comprising the amino acid sequence of SEQ ID NO:48; or 3. CDRL1 comprising the amino acid sequence of SEQ ID NO:51; CDRL2 comprising the amino acid sequence of SEQ ID NO:52; and CDRL3 comprising the amino acid sequence of SEQ ID NO:53; and b. a second antigen binding domain that binds to GPC3, wherein the second antigen binding domain comprises: i. a second heavy chain variable region, the second heavy chain variable region comprising: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 1; a CDRH2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDRH3 comprising the amino acid sequence of SEQ ID NO: 3; and ii. a second light chain variable region, the second light chain variable region having:
1. CDRL1 comprising the amino acid sequence of SEQ ID NO: 26; CDRL2 comprising the amino acid sequence of SEQ ID NO: 27; and CDRL3 comprising the amino acid sequence of SEQ ID NO: 28; or 2. CDRL1 comprising the amino acid sequence of SEQ ID NO:31; CDRL2 comprising the amino acid sequence of SEQ ID NO:32; and CDRL3 comprising the amino acid sequence of SEQ ID NO:33; or 3. CDRL1 comprising the amino acid sequence of SEQ ID NO:36; CDRL2 comprising the amino acid sequence of SEQ ID NO:37; and CDRL3 comprising the amino acid sequence of SEQ ID NO:
38. 9 . The bispecific antibody of claim 8 , wherein the first heavy chain variable region and the second heavy chain variable region comprise the amino acid sequence of SEQ ID NO:
4. 10 . The bispecific antibody according to claim 8 , wherein the first heavy chain and the second heavy chain comprise the amino acid sequence of SEQ ID NO:
5.
11. The bispecific antibody according to any one of claims 8 to 10, wherein for the first light chain variable region: a. Part a.ii.
1. includes the amino acid sequence of SEQ ID NO:44; b. part a.ii.
2. comprising the amino acid sequence of SEQ ID NO:49; or c. Part a.ii.
3. includes the amino acid sequence of SEQ ID NO:
54.
12. The bispecific antibody according to any one of claims 8 to 11, wherein for the first light chain: a. Part a.ii.
1. includes the amino acid sequence of SEQ ID NO:45; b. part a.ii.
2. comprising the amino acid sequence of SEQ ID NO:50; or c. Part a.ii.
3. includes the amino acid sequence of SEQ ID NO:
55.
13. The bispecific antibody according to any one of claims 8 to 12, wherein for the second light chain variable region a. Part b.ii.
1. includes the amino acid sequence of SEQ ID NO:29; b. Part b.ii.
2. comprising the amino acid sequence of SEQ ID NO: 34; or c. Part b.ii.
3. includes the amino acid sequence of SEQ ID NO:
39.
14. The bispecific antibody according to any one of claims 8 to 13, wherein for the second light chain: a. Part b.ii.
1. includes the amino acid sequence of SEQ ID NO:30; b. Part b.ii.
2. includes the amino acid sequence of SEQ ID NO: 35; or c. Part b.ii.
3. includes the amino acid sequence of SEQ ID NO:
40.
15. The bispecific antibody according to any one of claims 1 to 14, wherein the first light chain is κ and the second light chain is λ.
16. The bispecific antibody according to any one of claims 1 to 14, wherein the first light chain is λ and the second light chain is κ.
17. The bispecific antibody of any one of claims 1 to 16, wherein the bispecific antibody comprises an Fc domain comprising one or more amino acid substitutions that reduce binding to an activating Fc receptor and / or reduce effector function.
18. The bispecific antibody of claim 17, wherein the amino acid substitutions comprise L234A and L235A substitutions.
19. The bispecific antibody according to claim 17 or 18, wherein the amino acid substitutions comprise: i) L234A substitution; ii) L235A substitution; and iii) P329A, P329G or P329R substitution.
20. The bispecific antibody according to any one of claims 1 to 19, wherein the antibody has an IgG isotype.
21. The bispecific antibody according to any one of claims 1 to 20, wherein the antibody is a human antibody.
22. A composition comprising the bispecific antibody according to any one of claims 1 to 21.
23. A composition comprising the first bispecific antibody according to claim 1 and the second bispecific antibody according to claim 8.
24. The composition according to any one of claims 22 to 23, wherein the composition enables tumor-specific T cell activation.
25. A method of reducing the proliferation of and / or killing cancer cells, the method comprising contacting the cells with a composition according to any one of claims 22 to 24.
26. A method of treating cancer in a subject, the method comprising administering to the subject a composition according to any one of claims 22 to 24.
27. The method of claim 25 or 26, wherein the cancer is GPC3 positive.
